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ABSTRACT OF DISSERTATION 
  
 
GENOTOXIN-INDUCED ACETYLATION OF THE WERNER SYNDROME 
PROTEIN (WRN) AND EFFECT ON ITS DNA METABOLIC FUNCTION 
 
Loss of function of the WRN protein causes the genetic disorder Werner Syndrome that 
is characterized by increased cancer and premature aging. WRN belongs to the RecQ 
helicase family that plays key roles in preventing genome instability. In response to 
treatment with genotoxins, WRN is subject to post-translational modification. The 
relationship of post-translational modification of WRN with its function in DNA 
metabolism is unknown. There is accumulating evidence suggesting that WRN 
contributes to the maintenance of genomic integrity through its involvement in DNA 
replication. Consistent with this notion, WS cells are sensitive to DNA replication 
inhibitors and DNA damaging agents that tend to block replication fork progression. The 
cells exhibit an extended S phase, as well as defects in normal bi-directional progression 
of replication forks diverging from the majority of replication origins. To elucidate the 
relationship between post-translational modifications of WRN with its function in DNA 
metabolism, here the acetylation of WRN was studied. In our studies, we provide 
evidence that WRN acetylation is a dynamic process that strongly correlates to blockage 
of replication by persistent DNA damage. We also determined the effect of WRN 
acetylation on its specificity and enzymatic functions. In addition, our studies reveal how 
agents that block replication regulate the nature of WRN interactions with RPA, a factor 
known to bind to single-stranded DNA generated at blocked replication forks. Our results 
demonstrated that WRN and RPA form a stable direct association under normal 
physiological conditions and treatments that block replication fork progression increase 
their association, further supporting the idea that WRN is involved in DNA replication 
through its action at blocked or stalled replication forks. Thus, these studies point to both 
1) an important role for acetylation of WRN and 2) its interaction with RPA in the 
putative function of WRN in response to blocked replication. Overall, our results impact 
knowledge regarding the relationship between DNA damage, genome instability and the 
development and progression of aging and cancer.  
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CHAPTER I 
  
INTRODUCTION 
 
 WERNER SYNDROME                   
 
     Werner Syndrome (WS) is a rare autosomal recessive genetic disease caused by a 
deficiency of a single gene product known as WRN. This syndrome was first identified 
by Otto Werner, a German scientist who described the syndrome in his doctoral thesis in 
1904. WS is characterized by increased cancer and early onset or increased frequency of 
specific age-related phenotypes, including graying and loss of hair, skin ulceration, 
atherosclerosis, osteoporosis, cataracts, hypertension, and diabetes mellitus type II [Goto 
et al., 1997; Chen et al., 2002; Orren 2006]. The syndrome has specific symptoms not 
found in normal aging, including short stature, hyperkeratosis and soft tissue 
calcification. WS patients usually develop normally until they reach the second decade of 
life. In fact, most WS patients are not diagnosed until their 20’s or even 30’s. The median 
age of patients who die from WS is 54.  Primarily they die from cancer or cardiovascular 
disease [Huang et al., 2006]. Because of this large overlap with normal aging, the 
relatively normal early development, and the mildness of aging symptoms, it is believed 
that WS is an excellent model system for the study of human aging [Martin et al., 1978].  
 
ROLE OF WRN IN GENOME MAINTENANCE 
 
     Cells from WS patients show several distinct abnormalities when compared with 
normal cells, including elevated frequency of spontaneous chromosomal aberrations 
characterized by deletions, insertions, and translocations as well as an increased rate of 
telomere shortening [Gebhart et al., 1988; Honma et al., 2002].  In an effort to determine 
the role of WRN in DNA metabolism, WRN-deficient cells have been subjected to many 
DNA damaging regimens. They are hypersensitive to DNA damaging agents such as 4-
nitroquinolone-1-oxide (4NQO), interstrand crosslinking agents including mitomycin C 
(MMC) and cisplatin, and topoisomerase inhibitors such as camptothecin [Gebhart et al., 
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1988; Ogburn et al., 1997; Poot et al., 1999]. In addition, they are hypersensitive to 
agents that tend to block progression of replication forks, including hydroxyurea (HU) 
[Pichierri et al., 2001]. Together, this evidence suggests that WRN functions in cellular 
responses to maintain genome stability, such as DNA repair, replication and/or 
recombination pathways.  However, the sensitivity of WS cells to damaging agents does 
not appear to reflect a direct role in an established DNA repair pathway. Instead, 
sensitivity to certain DNA damaging agents and HU suggest that WRN plays a role in 
responding to replication blockage by lesions or other obstructions.  
 
     Additional evidence supports the role of WRN in DNA replication. WRN expression 
is upregulated during S phase in highly proliferative transformed cell lines [Kawabe et 
al., 2000b]. WS cells have dramatically reduced replicative capacity leading to very early 
cellular senescence; they grow slowly and have been reported to have a longer S phase as 
well as possibly replication initiation and elongation abnormalities [Martin et al., 1970; 
Takeuchi et al., 1982b; Salk et al., 1985; Poot et al., 1992; Yan et al., 1998]. WRN-
deficient cells are defective in normal bi-directional progression of replication forks 
diverging from the majority of replication origins [Rodriguez-Lopez et al., 2002]. This 
suggests a high frequency of replication fork stalling and is consistent with the notion that 
WRN may play an important but non-essential role in replication [Takeuchi et al., 1982a; 
Hanaoka et al., 1985].  Thus, it has been suggested that WRN is involved either in 
preventing the collapse of stalled replication forks or in resolving intermediates present at 
blocked forks. Consistent with this idea, recent studies have shown that:  1) upon 
replication arrest, WRN is redistributed to distinct nuclear foci (where it co-localizes with 
RPA) and is phosphorylated and acetylated [Constantinou et al., 2000; Sakamoto et al., 
2001; Blander et al., 2002], and 2) WRN can coordinate its unwinding and pairing 
activities to regress a model replication fork substrate [Machwe et al., 2006 and 2007]. 
From these observations (summarized in Table 1.1), it seems likely that WRN plays a 
role in a DNA metabolic pathway that allows the cell to properly deal with blockage of 
replication forks. Thus, the nature of genomic instability, increased cancer and premature 
aging observed in WS may be the result of improper resolution of blocked replication and 
illegitimate recombination caused by loss of WRN function. 
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Table 1.1 Evidence indicating a role of WRN in the maintenance of genomic integrity 
through its involvement in DNA replication 
Findings  References   
 
WS cells exhibit a reduced replicative life span. 
 
Martin et al., 1970; Salk et al., 1985 
 
 
WS cells exhibit an extended S phase.  
 
Takeuchi et al., 1982b; Poot et al., 1992 
 
 
WS cells are hypersensitive to agents that tend to 
block progression of replication forks. 
 
Gebhart et al., 1988; Ogburn et al., 1997; Pichierri et al., 
2001; Poot et al., 1999, 2001 
 
 
 
WRN moves to nuclear foci that correspond to sites 
of ongoing replication following HU and DNA 
damaging treatments. 
 
Karmakar et al., 2005; Sakamoto et al., 2001; 
Constantinou et al, 2000 
 
WRN expression is upregulated during S phase in 
highly proliferative transformed cell lines. 
 
Kawabe et al., 2000b 
 
WS cells are defective in normal bi-directional 
progression of replication forks diverging from the 
majority of replication origins 
 
 
Rodriguez-Lopez et al., 2002 
 
WRN regress model replication forks in vitro. 
 
Machwe et al., 2006 and 2007 
 
 
Functional and physical interaction with RPA, 
FEN-1, PCNA, Topoisomerase I, and DNA 
Polymerase δ 
 
Shen et al., 1998a, 2003; Brosh et al., 1999; Doherty et 
al., 2005; Sommers et al., 2005 ; Brosh et al., 2001, 
2002; Sharma et al., 2004 and 2005 ; Lebel et al., 1999; 
Rodriguez-Lopez et al., 2003 ; Lebel et al., 1999, Lane 
et al.,2003 ; Kamath-Loeb et al., 2000, 2001; Szekely et 
al., 2000 
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     It is well known that WRN associates or interacts directly with factors involved in 
DNA replication (references in Table 1.1).  For example, WRN interacts with proteins 
required for lagging strand synthesis such as PCNA and FEN-1.  The interaction with 
PCNA is remarkable since PCNA has key roles in important processes, besides DNA 
replication, such as DNA repair and recombination. WRN also interacts physically and 
functionally with RPA that protects single-stranded DNA and binds to gaps at blocked 
replication forks. What is more, Topo I, a protein that facilitates DNA replication by 
relaxing the tension generated by winding/unwinding of DNA, interacts with WRN. This 
interaction is not only physical but also functional; since WRN stimulates the ability of 
Topo I to relax negatively supercoiled DNA and Topo I inhibit the ATPase activity of 
WRN. However, the direct link of WRN involvement in DNA replication is its 
interaction with DNA polymerase δ, a major replicative DNA polymerase. Taken 
together, these observations suggest that WRN is involved in maintaining functional 
DNA replication forks and absence of these interactions in WS cells might contribute to 
the inability of those cells to properly respond to blockage of replication.  
 
POST-TRANSLATIONAL MODIFICATIONS OF WRN 
 
     WRN is subject to post-translational modifications that modulate the localization and 
activities of WRN upon DNA damage (Figure 1.1 summarizes the results of the latest 
studies in WRN modification). Among the most common post-translational modifications 
are phosphorylation, sumoylation and acetylation, all of which have been reported for 
WRN.  
 
     The first reported post-translational modification on WRN was sumoylation when 
endogenous and ectopically expressed WRN was shown to be modified by ubiquitin-like 
SUMO-1 molecules within cells. Conjugation of SUMO to WRN has been shown to be 
promoted by the nucleolar tumor suppressor p14 and the SUMO-conjugating enzyme 
Ubc9 [Kawabe et al., 2000a; Woods et al., 2004]. This modification correlates with WRN  
redistribution within the nucleus, suggesting that sumoylation might affect the 
availability or localization of WRN.    
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Figure 1.1 Functional consequences of WRN post-translational modifications 
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     In addition, it has been reported that WRN is phosphorylated at multiple ser/thr 
residues after DNA damaging treatments (including MMC and bleomycin) and other 
agents that block DNA replication (such as HU) [Pichierri et al., 2003; Karmakar et al., 
2002 and 2005; Yannone et al., 2001; Ammazzalorso et al., 2010]. DNA-dependent 
protein kinase (DNA-PK) was reported to be involved in WRN phosphorylation in vitro 
and is required for WRN phosphorylation in vivo [Yannone et al., 2001; Karmakar et al., 
2002]. Interestingly, phosphorylation of WRN with DNA-PK inhibits its helicase and 
exonuclease activities, suggesting that WRN modifications may be a way of regulating 
WRN catalytic activities. The proteins ATR and ATM, members of the phosphoinositide 
3-kinases family (PI3-Ks), as DNA-PK, phosphorylate WRN as well. ATR/ATM-
dependent WRN phosphorylation affects WRN translocation and co-localization with its 
protein partners, including RPA, in nuclear foci after DNA damage [Pichierri et al., 2003; 
Ammazzalorso et al., 2010]. Additionally, it was found that the nuclear tyrosine kinase c-
Abl regulates WRN phosphorylation. c-Abl phosphorylates WRN at tyrosine residues 
correlating with the translocation of WRN from nucleoli to discrete nuclear foci upon 
DNA damage [Cheng et al., 2003].   
 
     In addition to being sumoylated and phosphorylated, WRN is also acetylated in vivo 
[Blander et al., 2002]. WRN acetylation is promoted by the acetyltransferase p300. 
Interestingly, deacetylated WRN is localized in the nucleolus and acetylation of WRN 
correlates with its recruitment to the nucleoplasm. Furthermore, Karmakar and colleagues 
reported that DNA damaging agents, including MMC, promote WRN acetylation 
[Karmakar et al., 2005]. Taken together, it is likely that cellular WRN trafficking and 
activity is regulated by several types of post-translational modifications, which in turn 
may be related to a specific DNA damage response pathway.        
 
WERNER SYNDROME (WRN) GENE 
      
     The gene known to be defective in WS is located on the short arm of chromosome 8 
between positions 12 and 11.2. It was initially localized by linkage analysis, and the use 
of markers that were found to be in linkage disequilibrium in WS patients [Goto et al., 
 
7 
 
1992; Schellenberg et al., 1992; Thomas et al., 1993; Ye et al., 1995]. Finally, it was 
identified in 1996 by positional cloning. The discovery of the gene was viewed as 
significant, not only because a gene associated with aging was identified, but because it 
also turned out to be a cancer susceptibility gene [Yu et al., 1996; Nakura et al., 1996]. 
The WRN gene spans more than 250 kb and consists of 35 exons (from those, only 34 are 
coding exons) that encode a protein of 1,432 amino acids [Yu et al., 1997]. The gene was 
cloned by the Martin and Schellenberg groups at the University of Washington, and its 
coding sequence immediately suggested a role in DNA metabolism. The existence of 7 
conserved sequence motifs, typical of proteins with ATPase and/or helicase activity, 
placed WRN in the RecQ helicase family [Yu et al., 1996]. 
 
WRN AS A RECQ MEMBER 
      
     In general, helicases use the energy derived from the hydrolysis of ATP to catalyze the 
unwinding of double-stranded nucleic acids. The RecQ helicases are a subfamily of DNA 
helicases that are highly conserved through evolution [Bachrati et al., 2003]. Prokaryotes 
and lower eukaryotic species generally contain a single RecQ family member, including 
Sgs1 in Saccharomyces cerevisiae and RecQ in Escherichia coli. However, higher 
organisms contain multiple RecQ members. The human genome contains at least five 
RecQ genes (WRN, BLM, RECQ4, RECQ1, and RECQ5) that encode seven distinct 
proteins including three isoforms of RECQ5 generated by alternative splicing [Bachrati et 
al., 2008]. All RecQ helicases share a centrally located domain of ~450 residues that 
contains the seven conserved helicase motifs (see Figure 1.2). Downstream of the 
helicase domain, some RecQ members have additional regions of homology, known as 
the RecQ-conserved (RQC) and the Helicase and RNase D C-terminal (HRDC) domains.   
 
 
 
 
  
 
 
8 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic representations of RecQ family members. The name of the 
organisms and the proteins are listed on the right. The proteins are aligned with respect to 
their conserved helicase domain (in red). The less conserved RQC and HRDC domains, 
discussed in the text, are depicted in yellow and orange, respectively. WRN also contains 
an exonuclease domain (in purple) and a 27 residue direct repeat (in light blue). The NLS 
sequences are shown in dark blue.   
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     In general, loss of function of a RecQ member results in higher levels of illegitimate 
recombination, although the resulting types of chromosomal instability can vary 
somewhat. Thus, RecQ helicase appear to have prominent roles in the maintenance of 
genome stability, although the precise details of their roles in DNA metabolism are still 
unknown. Germ-line defects in three of the five human known RecQ helicases are 
associated with hereditable diseases. Specifically, defects in WRN, BLM or RECQ4 
result in Werner, Bloom or Rothmund-Thomson Syndrome, respectively. Individuals 
with these diseases are highly cancer-prone, but those with Bloom and Rothmund-
Thomson have fewer aging characteristics than WS patients [Martin et al., 2000].  
 
PROPERTIES OF THE WRN PROTEIN 
  
     WRN has an approximate molecular weight of 162 kilodaltons [Chen et al., 2002]. It 
has several structural domains (schematically depicted in Figure 1.3) that contribute to its 
physiological function. Several laboratories, including ours, have overproduced and 
purified recombinant WRN protein and characterized its domains and the basic catalytic 
activities associated with them. This section briefly describes each of those domains and 
the catalytic activities or properties related with them.   
  
     Several studies have demonstrated that WRN possesses DNA-binding activity. In fact, 
it has four distinct DNA-binding regions, including the helicase, RQC and HRDC 
domains [Liu et al., 1999; von Kobbe et al., 2003; Hu et al., 2005; Lee et al., 2005]. Its 
exonuclease domain also possesses DNA-binding affinity, albeit much weaker than the 
aforementioned domains [Machwe et al., 2006a]. Importantly, the DNA binding activity 
of WRN appears to be dependent upon DNA structure with no apparent nucleotide 
sequence preference [Orren et al., 1999; Brosh et al., 2002a].  It has higher affinity to 
single-stranded than for double-stranded DNA [Orren et al., 1999], in a manner 
influenced by substrate length [Machwe et al., 2006a]. WRN binds most stably, and has 
higher affinity, to complex DNA structures including substrates containing bubbles and 
D-loops [Orren et al., 2002; Shen et al., 2000; Brosh et al., 2002a].  
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Figure 1.3 Schematic representations of the domains of WRN. The domains of 
interest are depicted and identified.  
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     Consistent with its strong homology to RecQ helicases, the central region of WRN 
confers ATPase activity that provides the energy for unwinding DNA with a 3’→5’ 
directionality [Gray et al., 1997; Suzuki et al., 1997; Shen et al., 1998a].  This unwinding 
activity is highly DNA structure-specific in its action. It prefers special DNA structures, 
such as those formed during replication and recombination, including forks, bubbles, and 
Holliday junction intermediates [Constantinou et al., 2000; Brosh et al., 2001a; 
Mohaghegh et al., 2001; Lebel et al., 1999; Orren et al., 2002; Opresko et al., 2004]. 
Interestingly, our laboratory has demonstrated that, similar to some recombination 
proteins, WRN also facilitates the pairing of complementary DNA strands [Machwe et 
al., 2005]. This annealing activity acts in concert with its helicase activity to perform 
strand exchange, branch migration, and regression of model replication forks 
[Constantinou et al., 2000; Machwe et al., 2005, 2006b and 2007]. Thus, these facts 
suggest that WRN might be involved in recombination and/or replication-related 
pathways to maintain genome stability.    
 
     The existence of an N-terminal RNase D-type domain, not present in other human 
RecQ members, confers to WRN an intrinsic 3’→5’ exonuclease activity [Huang et al., 
1998; Shen et al., 1998b; Mian et al., 1997]. Thus, the unique premature aging phenotype 
of WS may be due to the loss of both helicase and exonuclease functions of WRN in 
DNA metabolic pathways. Biochemical analysis of WRN exonuclease activity indicates 
that the enzyme prefers the degradation of DNA duplex with a recessed 3’ end and 
alternate structures such as an internal bubble, D-loops and Holliday junctions [Orren et 
al., 2002; Shen et al., 2000; Machwe et al., 2002]. Interestingly, a recombinant WRN 
without the ATPase/helicase domain retains exonuclease activity [Huang et al., 1998], 
indicating that the exonuclease domain folds into a functional unit that can be uncoupled 
from WRN helicase activity. Although several biochemical studies have examined 
possible coordination between the helicase and exonuclease activities of WRN, whether 
and how they might act together in vivo remains unclear. 
 
      WRN has a direct repeat of a highly acidic 27-amino acid sequence localized between 
the region containing the exonuclease and helicase activities. This acid repeat has been 
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shown to be involved in protein-protein interaction such as the WRN and RPA 
interaction [Doherty et al., 2005]. The C terminus contains the nuclear localization signal 
(NLS). Individuals with WS have WRN gene mutations that truncate the gene product 
prior to the NLS. This has lead to the theory that the observed aging phenotypes result 
from the total absence of WRN’s nuclear functions.  
 
     In summary, WS is a well-established model system for investigating the relationships 
between chromosomal instability and development of cancer and other age-related 
diseases. At the cellular level, WRN deficiency results in replication abnormalities, 
extended S-phase, and hypersensitivity to certain DNA-damaging and replication 
blocking agents. In normal cells, subsequent to DNA-damaging treatments or HU, WRN 
is recruited to distinct nuclear foci and co-localizes with replication factors. WRN 
preferentially acts on complex DNA structures, such as those formed during replication 
and recombination. Collectively, this evidence indicates that WRN may play an 
important role in response to replication blockage. 
  
RESEARCH OBJECTIVES 
 
     Accumulating evidence indicates that WRN has a critical function for maintaining 
genomic stability. Consistent with its putative role in DNA metabolism, WRN is 
localized in the nucleus. However, upon DNA damage and blockage of replication, WRN 
migrates into discrete nuclear foci. These subnuclear foci are sites of ongoing or arrested 
DNA replication, supporting WRN function in restoration of blocked replication. In 
support of a replication-related role for WRN, it colocalizes with the replication factor 
RPA in replication foci. The latter suggests that WRN and RPA might interact at stalled 
replication forks, influencing WRN role in accurate resolution of replication blockage. 
Importantly, this WRN redistribution correlates with WRN acetylation, suggesting that 
this post-translational modification may regulate WRN function at blocked replication 
forks. The fact that WRN catalytic activities have preference in resolving unusual DNA 
structures and regressing model replication forks are also consistent with a function of 
WRN in remodeling or resolving blocked replication forks.  
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     The goal of this study is to further clarify the role of WRN in response to agents that 
damage DNA and/or block replication, with a particular emphasis on the relationship of 
acetylation of WRN with its function in DNA metabolism. The specific hypothesis is that 
blockage of replication by DNA damage in the template or other circumstances 
(nucleotide depletion, in the case of HU) induces translocation and acetylation of WRN 
to perform a key function in proper resolution of these obstructions to replication. In the 
absence of WRN, when replication undergoes pausing as in the case of nucleotide 
depletion or arrest at the site of DNA damage, the cell cannot properly resolve the 
resulting structures. Subsequently, collapse of the replication fork causes double-strand 
break formation and increased illegitimate recombination. This is highly consistent with 
the increased genomic instability observed in WRN-deficient cells.  Thus, to investigate 
the events surrounding the potential function of WRN in response to DNA damage and 
replication blockage, our studies have been focused on WRN acetylation to determine its 
impact on the role of WRN in DNA damage response. The specific aims are: 1) to study 
the dynamics of WRN acetylation and its relationship to DNA damage, 2) to investigate 
the effect of WRN acetylation on its biochemical functions, and 3) to study if the nature 
of WRN interaction with RPA is altered in response to agents that block replication. Our 
findings should help to determine an important role for WRN in maintaining genome 
integrity and whether and to what extent acetylation of WRN contributes to genomic 
integrity surveillance. 
  
This study has addressed the following issues in three chapters:  
 
Chapter 2 – Genotoxin-induced WRN dynamic acetylation and its correlation to blockage 
of replication by persistent DNA damage 
 
Chapter 3 – WRN acetylation regulates its enzymatic activities 
 
Chapter 4 –WRN interaction with RPA in response to agents that block replication 
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    CHAPTER II 
 
GENOTOXIN-INDUCED WRN DYNAMIC ACETYLATION AND ITS 
CORRELATION TO BLOCKAGE OF REPLICATION BY PERSISTENT DNA 
DAMAGE 
 
INTRODUCTION 
 
    DNA damage may induce post-translational modification of proteins to allow proteins 
to be regulated in a temporal and spatial manner, in most cases to ensure efficient 
regulation of cellular processes in response to genotoxic stress. [Appella et al., 2001; 
Huen et al., 2008; Polo et al., 2011]. The most common and well-studied protein 
modifications are acetylation, sumolyation, ubiquitylation, methylation and 
phosphorylation. The importance of post-translational modification is highlighted by the 
results of several recent studies that demonstrate interplay between multiple protein 
modifications that combine to propagate the DNA damage signal to elicit cell cycle 
arrest, DNA repair, apoptosis and senescence [Huen et al., 2008]. Recent studies have 
shown that WRN is subject to post-translational modifications in response to several 
DNA damaging agents. Specifically, WRN is subject to acetylation, sumoylation and 
phosphorylation [Blander et al., 2002; Karmakar et al., 2002 and 2005; Pichierri et al., 
2003; Yannone et al., 2001]. The work presented here has focused on WRN acetylation 
to investigate the impact of this modification on the function of WRN in DNA 
metabolism.   
 
     First identified for histones over 40 years ago, acetylation of lysine residues of 
proteins is now known to occur in more than 80 transcription factors, many nuclear 
regulators, and various cytoplasmic proteins. It is emerging as a key mechanism by which 
proteins are regulated in several physiological processes such as migration, metabolism 
and aging [reviewed on Close et al., 2010 and Choudhary et al., 2009]. In humans, the 
acetylation state of proteins is determined by two main groups of enzymes [Figure 2.1]. 
The first one is the group of histone aceyltransferases (HATs), also called acetylases,  
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Figure 2.1 Protein Acetylation. The acetylation process involves two main groups of 
proteins: 1) Acetylases (including GNC5, CBP/p300, PCAF and the MORF complex) 
that are responsible for adding the acetyl groups onto lysines in proteins, and 2) 
Deacetylases that remove acetyl groups from lysine amino acids. The main ones are the 
histone deacetylases (HDACs) and the sirtuins (SIRTs). HDACs are usually found as 
multisubunit complexes with proteins containing histone deacetylase and remodeling 
activities, such as NURD, and corepressors such as SMRT/NcoR and Sin3. 
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that are responsible for adding the acetyl groups onto lysine of proteins. Of these 
enzymes, the p300/CBP family is the most characterized and continues to receive the 
most attention. The second group of enzymes is known as deacetylases that remove 
acetyl groups from lysine amino acids in proteins. The main ones are the histone 
deacetylases (HDACs) and the sirtuins that include seven members (SIRT1-7). The 
importance of these enzymes is highlighted by the fact that aberrant protein acetylation 
and deacetylation activity is associated with various diseases, including solid tumors and 
leukemias [Marks et al., 2010; Cress et al., 2000]. Given their association with cancer 
formation, novel compounds endowed with a deacetylase inhibitory activity, such as 
nicotinamide and Trichostatin A, have gained interest as both cancer chemopreventive 
and therapeutic agents [Federico et al., 2011]. 
 
     It has been demonstrated that acetylation may affect the function of a protein, the 
nature of the interaction with its protein partners, and the sub-cellular localization. For 
example, acetylation of the genomic guardian and tumor suppressor p53 has been shown 
to be induced by DNA damaging agents resulting in alteration of its ubiquitination, 
stability and nuclear localization [Liu et al., 1999; Zhao et al., 2006; Chao et al., 2006].  
In addition, p53 acetylation regulates the interaction of p53 with its protein partners 
(including Mdm2) and its ability to increase transcription of p21 and suppress cell growth 
[Tang et al., 2008; Zhao et al., 2006].  Together, these findings indicate that acetylation 
can play a key role exerting multifaceted effects to control various cellular and biological 
processes in vivo.  
   
     Recent studies have shown that the cellular function of WRN appears to be regulated 
by acetylation. Specifically, Blander and colleagues reported that WRN acetylation in 
vivo is promoted by the acetyltransferase p300 [Blander et al., 2002]. Moreover, it has 
been shown that deacetylated WRN is localized in the nucleolus and that acetylation of 
WRN correlates with its translocation to nuclear foci (where WRN colocalizes with PML 
nuclear bodies that are known to contain protein acetyltransferases); these discrete 
subnuclear regions correspond to sites of ongoing and/or blocked DNA synthesis in 
which WRN co-localizes with replication factors (such as RPA) in response to DNA 
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damaging agents and the replication inhibitor HU [Constantinou et al., 2000; Blander et 
al., 2002; Karmakar et al., 2005]. Taken together, it is likely that regulation of WRN 
within cells is altered by protein acetylation, and perhaps is related to its function in a 
specific DNA metabolic pathway.  
 
     In order to further understand the regulation of WRN by protein modification, we 
studied the relationship between DNA damage, inhibition of DNA replication and WRN 
acetylation. Although some studies indicate potential roles for acetylation in WRN 
regulation, it remains unclear the circumstances in which WRN becomes acetylated and 
how is WRN specifically regulated by acetylation. In this chapter, we report that WRN is 
detectably acetylated under normal conditions and that acetylation of WRN significantly 
increases after treatment with DNA damaging agents and inhibitors of DNA replication. 
Importantly, we provide evidence that it is not simply the induction of damage but its 
persistence that enhances WRN acetylation. The kinetics of WRN acetylation, its cell 
cycle relationship and the roles of HDACs and sirtuins in regulation of WRN acetylation 
were also investigated.  Together, these studies advance our understanding of the 
dynamics of WRN modification in response to DNA damage. 
 
RESEARCH DESIGN      
 
SPECIFIC AIM: To study the dynamics of WRN acetylation and its relationship to 
DNA damage. 
 
Aim  a.   To establish methods to measure endogenous WRN acetylation  
Aim b. To investigate the relationship between DNA damage and/or replication 
blockage and WRN acetylation   
Aim b1. To determine the influence of DNA damaging agents and/or replication    
inhibitors on WRN acetylation levels 
Aim b2. To examine whether WRN acetylation is directly related to induction of 
DNA damage and/or its persistence  
      Aim b3. To establish the kinetics and cell cycle relationship of WRN acetylation 
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Aim c. To study the roles of HDAC and sirtuins deacetylases in regulation of WRN 
acetylation 
 
RATIONALE  
  
     The cellular function of WRN appears to be regulated by posttranslational 
modification [Kusumoto et al., 2007], including acetylation. Consistent with this idea, 
WRN modification correlates with its translocation to nuclear foci in response to DNA 
damage and replication blockers [Blander et al., 2002; Karmakar et al., 2005]. It is well 
established that DNA damage and blockage of replication may induce post-translational 
modifications to allow temporal and spatial control over the modified protein 
relocalization, interactions and function [Huen et al., 2008; Appella et al., 2001; Polo et 
al., 2011]. Collectively, these facts support the notion of an association between WRN 
modification and DNA damage and blockage of replication. To further elucidate the 
function of WRN in response to DNA damage, we wanted to investigate WRN 
acetylation in greater depth. We hypothesized in this study that DNA damaging agents 
and replication blocking agents induce WRN acetylation. First, we established a method 
to measure acetylation of endogenous WRN (Aim a). Then, we used this method to 
analyze if endogenous WRN acetylation is influenced in response to DNA damaging 
agents and replication inhibitors (Aim b1). If our hypothesis is true, increasing the 
frequency of damage should lead to increased levels of WRN acetylation. 
Experimentally, this can be accomplished by preventing removal of damage by standard 
repair pathways to determine if WRN acetylation is amplified after appropriate DNA 
damage when the DNA repair pathway involved in removing the induced damage is 
absent and/or defective (Aim b2). Since lysine acetylation is a reversible posttranslational 
process that could be related to detection and propagation of specific cellular responses 
[Huen et al., 2008], we analyzed the kinetics and potential relationship to cell cycle (Aim 
b3). Given that lysine acetylation is governed by the opposing actions of 
acetyltransferases and deacetylases, we analyzed the role of deacetylases in regulation of 
WRN acetylation (Aim c). Specifically, we studied whether WRN is a substrate for the 
activity of HDAC and sirtuin classes of deacetylase enzymes.        
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Aim a. To establish methods to measure endogenous WRN acetylation. Although 
expression systems have been use to examine acetylation of proteins, including WRN, the 
detection of endogenous acetylated WRN requires additional challenges and optimization 
of protocols to achieve high sensitivity. Thus, we established our own protocol to obtain 
better sensitivity and provide quantitative data. This was accomplished by analyzing the 
specificity of different commercially available antibodies against WRN and acetylated 
lysine residues in proteins during immunoprecipitation and immunoblotting techniques. 
The utility and validation of the approach was assessed by using purified wild-type and 
acetylated WRN. 
 
Aim b. To investigate the relationship between DNA damage and/or replication 
blockage and WRN acetylation. WRN-deficient cells are hypersensitive to several 
DNA damaging agents, including methylmethanesulfonate (MMS), mitomycin C (MMC) 
and cisplatin, and the replication inhibitor hydroxyurea (HU) [Poot et al., 2001; Imamura 
et al., 2002; Harrigan et al., 2006]. Since WRN function is needed for resistance to these 
agents, then it might be regulated in response to these treatments, including by post-
translational modification. As support for this idea, in normal cells WRN relocalizes from 
(primarily) the nucleolus to punctuate nuclear foci (also containing replicator factors) 
following treatment with MMS and DNA replication inhibitors [Karmakar et al., 2005; 
Constantinou et al., 2000]. This movement of WRN to nuclear foci correlates with WRN 
modification, specifically with WRN phosphorylation and acetylation [Pichierri et al., 
2003; Blander et al., 2002].  
 
     Since WRN cells are hypersensitive to MMS, MMC, cisplatin and HU, we used these 
agents to produce DNA damage or maximally block replication for the subsequent 
examination of WRN acetylation (aim b1). To determine if WRN acetylation is indeed 
related to DNA damage, we studied whether WRN modification is increased in cells with 
deficient or inhibited repair pathways after appropriate DNA damaging treatments (aim 
b2). Since cells with deficient or inhibited repair pathways cannot repair the lesions 
caused by specific DNA damaging agents, the damage will persist. If DNA damage 
results in WRN acetylation, then disabling specific DNA repair pathways should amplify 
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WRN acetylation. Thus, this strategy should help to establish whether the effect of the 
agent is specifically mediated by the DNA damage that it generates and to examine 
whether the response (acetylation) is related to initial damage induction or to the 
persistence of the DNA damage. If the latter is the case, this may imply a downstream 
effect of the damage on DNA metabolism. 
  
     Acetylation is a reversible posttranslational modification [Yang et al., 2004]. Thus, to 
establish the kinetics of WRN acetylation (aim b3), we studied the rate at which WRN is 
acetylated and the duration of this modification on WRN. To this end, WRN acetylation 
was monitored at several time points after MMS treatment. Importantly, such 
experiments should help to determine the kinetics of WRN acetylation as a function of 
time. It has been shown that protein acetylation status could be associated with (events 
occurring during) specific cell cycle phases. For example, PCNA acetylation has been 
shown to be related to S phase progression [Naryzhny et al., 2004]. Thus, as part of this 
study, we also sought to identify if WRN acetylation is associated with a specific phase 
of the cell cycle. This relationship was analyzed first by comparing the cell cycle profile 
of population of cells untreated or treated with a DNA damaging agent that induced 
WRN acetylation. The efficacy of the experiment was verified by flow cytometry 
following Hoechst staining of permeabilized cells. Then, to analyze if WRN acetylation 
has a relationship to DNA replication (or the lack thereof), DNA synthesis in the 
presence and absence of DNA damaging agents or replication inhibitors was directly 
measured by  bromodeoxyuridine (BrdU) incorporation, a synthetic thymidine analog 
that gets incorporated into a cell’s DNA during replication.  
 
Aim c. To study the roles of HDAC and Sirtuin deacetylases in regulation of WRN 
acetylation. The acetylation state of a protein is determined by the opposing action of 
acetylases and deacetylases. In this aim, we investigate the role of deacetylases in 
regulating WRN acetylation. To date, eighteen genes encoding proven or putuative 
deacetylases have been identified in humans [Johnstone et al., 2002; Witt et al., 2009]. 
These have been divided into four distinct classes based on based on their size, cellular 
localization, number of catalytic active sites, and homology to yeast HDAC proteins. 
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Class I, II, and IV are called the ‘‘classical” HDACs and Class III is known as sirtuins 
[Witt et al., 2009]. Therefore, we used drugs to inhibit the different classes of 
deacetylases: trichostatin A (TSA) selectively inhibits the Class I, II and IV of histone 
deacetylase enzymes and nicotinamide has been shown to inhibit the Class III that are the 
sirtuins [Moradei et al., 2005; Bieliauskas et al., 2008; Walkinshaw et al., 2008; Cen et 
al., 2010; Witt et al., 2009].  These inhibitors were used alone and in combination, as well 
as with DNA damaging agents, to investigate the dynamics of WRN acetylation and the 
roles of each class of deacetylases.   
 
METHODS 
 
Culture medium and reagents. The SV40-transformed fibroblast cell lines, 1-O and 8-
D, used in my experiments were obtained from J. Christopher States, University of 
Louisville. Methylmethanesulfonate (MMS), phenylmethylsulfonylfluoride (PMSF), 
TSA, nicotinamide, HU, MMC, cisplatin, O6-benzylguanine and protease inhibitor 
cocktail were purchased from Sigma-Aldrich. Olaparib was purchased from ChemieTek. 
Cell culture media and reagents were purchased from Invitrogen. Cells were grown in 
MEM-α Glutamax medium supplemented with 10% FBS, 1% HEPES, and 1% penicillin-
streptomycin at 37°C in a humidified atmosphere containing 5% CO2. For DNA 
damaging treatments, we chose MMS, MMC, and cisplatin. We also used the replication 
inhibitor HU. After we chose these drugs for our experiments, we initially treated 
actively growing, subconfluents populations of cells with doses reported from other 
studies representing physiological conditions. Then, we monitored toxicity by counting 
viable cells to establish the proper dose range to work. Cells were incubated in growth 
medium containing 1 mM MMS for 4 h, 2 mM HU for 16 h (or 10 h when indicated), 7 
µM MMC for 16 h or 25 µM cisplatin for 19 h before harvesting. For inhibition of 
deacetylases, cells were incubated in growth medium containing 1 µM TSA and/or 5 mM 
nicotinamide for 4 h or 10 h (as indicated in figures) in the presence or absence of MMS 
or HU. For inhibition of MGMT, cells were pre-incubated in growth medium containing 
40 µM O6-benzylguanine for 4 h followed by incubation with 1 mM MMS for an 
additional 4 h. For treatment with O6-benzylguanine alone, cells were treated with 40 µM 
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O6-benzylguanine for 8 h. To study the inhibition of PARP, cells were treated with 5 nM 
olaparib for 38 h followed by incubation with 1 mM MMS for an additional 4 h.  For 
treatment with olaparib alone, cells were treated with 5 nM olaparib for 42 h. 
 
Expression and purification of unmodified and acetylated WRN. Purified WRN 
proteins (unmodified and acetylated) were used for optimization of immunoprecipitation 
methods as well as for enzymatic studies (conducted as described in Chapter III). 
Recombinant unmodified WRN was expressed using the baculovirus-insect cell system 
as described [Orren et al., 1999]. FLAG-tagged WRN and FLAG-tagged acetylated WRN 
were overexpressed in HEK293 cells using a transient transfection assay (developed by 
Dr. Jianyuan Luo, University of Maryland Medical School). To obtain unmodified 
FLAG-WRN, cells were transfected with vector specifying production of FLAG-WRN. 
To obtain acetylated WRN, cells were co-transfected with individual vectors specifying 
production of FLAG-WRN and CMV-p300 or CMV-CBP (p300 and CBP are two 
acetyltransferases that acetylate WRN in vivo) [Blander et al., 2002]. To maximally 
acetylate WRN protein, cells were treated with TSA and nicotinamide to inhibit cellular 
deacetylase activity 6 h before harvest. To obtain deacetylated FLAG-WRN, cells were 
co-transfected with FLAG-WRN, CBP and SIRT1 (a histone deacetylase) vectors. Cells 
were harvested 36 h after transfection and were lysed in a FLAG-lysis buffer (50 mM 
Tris-HCl pH 7.8, 137 mM NaCl, 1 mM NaF, 1 mM NaVO3, 1% Triton X-100, 0.2% 
Sarkosyl, 1 mM DTT, 10% glycerol) containing fresh protease inhibitors, PMSF, 10 µM 
TSA and 5 mM nicotinamide. After anti-FLAG M2 immunoprecipitation, the 
immobilized FLAG-WRN proteins were released using FLAG peptide (Sigma) and 
purified unmodified or acetylated FLAG-WRN was collected. To determine relative 
protein concentration, the eluted protein products were resolved by 8% SDS-PAGE gels 
and analyzed by western blot with anti-WRN antibody (Santa Cruz Biotechnology). To 
determine the level of acetylation, the products were analyzed by western blot with anti-
acetylated lysine antibody (Cell Signaling). 
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Immunoprecipitation and detection of WRN acetylation. For immunoprecipitation 
experiments, cells were lysed by sonication in RIPA buffer (50 mM Tris-HCl (pH 7.4), 
150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, and 1 mM EDTA) supplemented 
with protease inhibitor cocktail, 1 mM PMSF and 10 units/ml of DNase I (New England 
Biolabs). After centrifugation at 21,000  g for 12 min at 4°C, the supernatants/clarified 
lysates were isolated and their protein concentrations measured. Aliquots of the clarified 
lysates (~600 ug of protein each) were then pre-cleared with Protein G Plus/Protein A 
agarose beads (Calbiochem) and 1 ug of normal mouse IgG (Santa Cruz) for 1 h, then 
incubated with anti-acetylated lysine antibody (Cell Signaling) and 30 μl of Protein G 
Plus/Protein A bead suspension for 18 h at 4°C. After collection by centrifugation and 
removal of supernatant, the beads were then washed three times with RIPA buffer 
supplemented with protease cocktail inhibitors, 1 mM PMSF and 200 ug/ml ethidium 
bromide. After removal of the final wash, equal portions of RIPA and 2X SDS sample 
buffer were added to the beads and immunoprecipitated proteins were released by heating 
at 95°C for 5 min. Equal volumes of each sample were resolved by SDS-PAGE (8%). For 
the loading control, 30-50 ug of each sample (as specified in figures) were also resolved 
by SDS-PAGE (8%). Proteins were transferred to PVDF membranes (Bio-Rad) by 
electroblotting. The membranes were blocked with 5% nonfat dry milk in TBST buffer 
(20 mM Tris, pH 7.4, 140 mM NaCl and 0.1% Tween-20) and analyzed by western 
blotting with mouse monoclonal anti-WRN (Abcam) antibody for 18 h at 4°C followed 
by incubation with peroxidase-labeled secondary anti-mouse (GE Healthcare) for 1 h at 
room temperature. Signal was visualized by chemiluminescent analysis using ECL Plus 
(GE Healthcare). 
 
Micronucleus Assay. 8-D and 1-O cells were incubated in growth medium without or 
with 25 µM Cisplatin for 19 h. After 19 h incubation, the media was removed and cells 
were washed twice with growth medium. New media was added to the cells and 
cytochalasin B (3 ug/mL, from Sigma-Aldrich) was added to the culture for 24 h. Cells 
were harvested, fixed (methanol:acetic acid 3:1) at 4°C and seeded onto microscope 
slides (75 x 25 mm, 1 mm thick from Fisher Scientific). Slides were air dried, then 
stained with a 10% Giemsa (Sigma-Aldrich) solution and examined at 1000× 
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magnification (oil) using a bright field microscope. One thousand (1000) binucleated 
cells per treatment were examined and the number of micronuclei was recorded. 
  
Flow Cytometry Analysis. 1-O cells were incubated in growth medium containing +/- 1 
mM MMS for 2 h. After incubation, cells were harvested and counted using a 
hemocytometer. Cells were suspended at a density of 5 × 106 cells/ml in sorting buffer 
[1× PBS (Ca/Mg++ free), 1 mM EDTA, 25 mM HEPES pH 7.0, 1% FBS (heat 
inactivated)]. Hoechst 33342 stain (10 µM, from Sigma-Aldrich) was added and cells 
were incubated at 37°C for 45 min (with mixing every 5 min). Cells were filtered thru a 
40 micron cell strainer (from Fisher Scientific) to remove clumps and debris. Cells were 
analyzed by flow cytometry and subsequently subjected to immunoprecipitation and 
immunoblotting as specified above.  
 
BrdU incorporation Assay. The assay was performed using a kit following the 
manufacturer instructions (Exalpha Biologicals BrdU cell proliferation assay). A 
suspension of 1-O cells (1.5 × 105 cells/ml) was prepared using culture media. 100 ul was 
added to each well (using 96-well tissue culture plates). After 8 h, cells were untreated, 
treated with 2 mM HU for 16 h, or treated with 1 mM MMS for 1-4 h (as indicated in 
figures). BrdU was added 1 h prior to the end of the treatments. Media was aspirated 
from the cell wells and cells were fixed (using a solution provided in the kit) at room 
temperature for 30 min. Cells were washed three times using the washing buffer provided 
by the manufacturer. An anti-BrdU monoclonal antibody was added and cells were 
incubated for 1 h at room temperature. Cells were washed three times and incubated for 
30 min at room temperature with peroxidase goat anti-mouse IgG conjugate. After three 
washes, TMB (3,3', 5,5"-tetramethylbenzidine) peroxidase substrate was added and cells 
were incubated for 30 min at room temperature in the dark. A stop solution was added to 
every well and the absorbance was measured at 450 nM using a spectrophotometric 
microtiter plate reader (SpectraMax Plus 384, Molecular Devices).      
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Statistical analysis. The data was analyzed using one-way ANOVA followed by 
Newman Keuls post-test (GraphPad Prism-4). A p value of less than 0.05 was considered 
a significance difference.  
 
RESULTS   
 
Protocol for detection of endogenous acetylated WRN. Previous studies show WRN 
modification and relocalization to nuclear foci after treatment with DNA damaging 
agents and blockers of replication.  In light of these findings, we reasoned that it should 
be possible to detect WRN modification, specifically WRN acetylation, particularly as a 
response to DNA damage and replication stress. Although experimental approaches exist 
to tease out the role of post-translational modifications on WRN, most of them have been 
based on ectopic expression of WRN. Because of a lack of methods and information on 
endogenous WRN modifications, we set out to establish our own protocol to measure 
endogenous WRN acetylation. First, we tested the specificity of different commercially 
available antibodies against WRN protein to detect unacetylated and acetylated WRN 
protein, produced as described in the Methods section. Then, we tested the ability of 
those antibodies to pull WRN from cell lysates. The specificity of different commercially 
available antibodies against acetylated lysine proteins (including an antibody against 
acetylated WRN) was also tested to determine if they can recognize purified acetylated 
FLAG-WRN protein. The capability of those antibodies to pull down acetylated WRN 
and their specificity was also established by adding purified acetylated WRN into cell 
lysates of WRN-deficient and -proficient cell lines. Finally, we tried different 
combinations of the antibodies to perform IP and immunoblotting techniques. From all 
the combinations tested, we decided to use an antibody against acetylated lysine for the 
IP reaction and an antibody against WRN to probe for acetylated WRN since that 
combination of antibodies gave us clean, consistent and highly sensitive western blots. 
Importantly, the selected antibody against WRN was able to identify both states 
(unacetylated and acetylated) of WRN (Figure 2.2A) and the antibody against acetylated 
lysine specifically recognizes the acetylated form of WRN (Figure 2.2B). In addition, the 
acetylated lysine antibody specifically pulled down the acetylated form of WRN (Figure  
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Figure 2.2 Specificity of antibodies selected for our studies. A) Unacetylated and 
acetylated recombinant WRN proteins were subjected to SDS-PAGE and Western 
blotting with anti-WRN antibody. B) Unacetylated and acetylated recombinant WRN 
proteins were subjected to SDS-PAGE and Western blotting with anti-acetylated lysine 
antibody. C) Cell lysates were subjected to immunoprecipitation by incubating with the 
specified antibodies (Ab) in the presence or absence of purified acetylated WRN. The IP 
products were subjected to SDS-PAGE and analyzed by Western blotting with anti-WRN 
antibody.  
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2.2C, compare lanes 3 and 4).  The diagram in figure 2.3 shows the established protocol. 
Briefly, after drug treatments, cell lysates were prepared and the protein concentration of 
each cell lysate was measured to use comparable amounts of each sample. Lysates were 
subject to a pre-clearing step to remove proteins that interacted non-specifically with 
normal IgG and Protein G Plus/Protein A beads. The pre-cleared lysates were incubated 
with a mouse monoclonal antibody against acetylated lysine to immunoprecipitate the 
pool of acetylated proteins. After release from the beads, immunoprecipitated proteins 
were separated by SDS-PAGE and analyzed by Western Blot using an antibody specific 
for WRN protein. The results were quantified using a fluorimager.  
DNA damaging agents/replication inhibitors enhance WRN acetylation. WS cells are 
hypersensitive to certain DNA damaging agents, including MMS, MMC and cisplatin. In 
addition, WS cells are hypersensitive to the replication inhibitor HU. Collectively, these 
findings suggest that WRN might be regulated in response to those treatments, including 
by post-translational modifications. Thus, we used these agents as possible candidates for 
the induction of WRN acetylation. As a negative control, cells were analyzed after UV-C 
irradiation, a treatment that does not cause enhanced cell death in WS cells compared to 
normal cells. MMS is a DNA-alkylating agent that methylates DNA bases, producing 7-
methylguanine, 3-methyladenine and O6-methylguanine [Wyatt et al., 2006]. MMC is a 
crosslinking agent that induces interstrand crosslinks [Dusre et al., 1989]. Cisplatin is a 
platinum-based chemotherapy drug that acts by generating mostly intrastrand crosslinks, 
repaired by nucleotide excision repair (NER), as well as some interstrand crosslinks 
[Jamieson et al., 1999]. HU depletes nucleotide pools by inhibition of the enzyme 
ribonucleotide reductase, resulting in blocking progression of all replication forks [Skog 
et al., 1992]. WS cells are hypersensitive to HU, apparently by apoptosis of cells with 
stalled replication forks [Pichierri et al., 2001]. UV-C causes direct photochemical 
damage to DNA producing covalent linkages between adjacent cytosine and thymidine 
bases creating cyclobutane pyrimidine dimers and 6-4 photoproducts [Sinha et al., 2002; 
Markovitsi et al., 2010]. Experiments were performed with human fibroblasts treated 
either with or without 1 mM MMS for 4 h, 2 mM HU for 16 h, 7 µm MMC for 16 h, 25 
µM cisplatin for 19 h or irradiated with 20 J/m2 or 40 J/m2 UV-C. Interestingly, a low  
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Figure 2.3 Schematic representation of the protocol used. 
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level of acetylation of WRN is detectable even in untreated cells (Figure 2.4A, lane 2). 
More importantly, the amount of acetylated WRN is significantly increased in cells 
treated with MMS, HU, MMC, and cisplatin (Figure 2.4A, upper panel, compare lines 2 
to 3-6). Quantitation of data from multiple independents experiments indicates that 
treatment with MMS results in 3.3 fold increase and treatment with HU in 2.1 fold 
increase in the levels of WRN acetylation. The crosslinking agents also increase the 
levels of acetylated WRN, since treatment with MMC and cisplatin resulted in 2.7- and 
2.5-fold increase (quantitation in Figure 2.4B), respectively. This effect was not due to an 
increase in WRN expression or abundance caused by any of the treatments, since a 
parallel Western analysis of lysates with anti-WRN antibody indicated that the same 
amount of total WRN is present following each treatment (Figure 2.4A lower panel). In 
contrast, irradiation of cells with 20 J/m2 or 40 J/m2 UV-C does not increase significantly 
the levels of acetylated WRN (Figure 2.4C, compare line 2 vs. lines 3 and 4, quantitation 
on figure 2.4D). Collectively, this data indicates that WRN acetylation is upregulated in 
response to certain DNA damaging treatments (but not UV) and replication inhibitors. 
 
Correlation between persistent DNA damage and WRN acetylation. Although the 
experiments above suggest an association between DNA damage and WRN acetylation in 
vivo, we wanted to confirm this relationship and investigate it further. Our strategy was to 
inhibit removal of particular types of DNA damage to increase the frequency of those 
lesions in the DNA template. If WRN acetylation is related to DNA damage, inhibition of 
repair pathways that remove the relevant type of damage should amplify the effect of the 
damaging agent on WRN acetylation. Thus, we monitored WRN acetylation in cells with 
normal and compromised repair pathways after appropriate DNA damaging treatments. 
     Initially, we focused on MMS because this agent gave us the highest increase in WRN 
acetylation. MMS methylates DNA at the N7-deoxyguanine, N3-deoxyadenine and O6-
deoxyguanine positions. Thus, we examined the effect of persistence of these adducts on 
WRN acetylation. The 7-methylguanine and 3-methyladenine adducts are repaired by 
base excision repair (BER) [Wyatt et al., 2006]. BER is involved in repair of DNA 
damage arising from spontaneous base loss or genotoxic agents that modify bases, such  
 
30 
 
 
Figure 2.4 WRN is acetylated in response to DNA damaging agents/replication 
inhibitors. A) 8-D cells were incubated  in growth medium with or without 1 mM MMS 
for 4 h, 2 mM HU for 16 h, 7 uM MMC for 16 h or 25 uM Cisplatin for 19 h (before 
harvest) and clarified cell lysates were processed for IP with anti-acetylated lysine 
antibody. The IP products were subjected to SDS-PAGE and western blotting with anti-
WRN antibody (upper panel). 50 ug of each cell lysate were subjected to SDS-PAGE and 
western blotting with anti-WRN antibody (lower panel) to ensure that equal amount of 
total WRN was present in the IP reactions as control. B) Quantitative bar graph for WRN 
acetylation (mean ± SEM of 3 independent experiments. * = P < 0.05 when compared 
with control untreated cells). C) Cells were irradiated (20 J/m2 or 40 J/m2 UV-C) or 
treated with 1 mM MMS for 4 h (before harvest) for IP with anti-acetylated lysine 
antibody. The IP products were subjected to SDS-PAGE and Western blotting with anti-
WRN antibody (upper panel). 40 ug of each cell lysate were subjected to SDS-PAGE and 
Western blotting with anti-WRN antibody (lower panel). D) Quantitative bar graph for 
WRN acetylation (mean ± SEM of 4 independent experiments. * = P < 0.05 when 
compared with control untreated cells). Lanes 1 in figure A and C are purified acetylated 
WRN (upper panel) or purified unmodified WRN (lower panel) that we used as marker 
(MKR).   
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 as MMS [Wyatt et al., 1999 and 2006; Horton et al., 2005]. The O6-methylguanine 
adducts are acted on by the enzyme O6-methylguanine methyltransferase (MGMT) that 
repairs O6-methylguanine by direct transfer of the alkyl group on guanine to a 
cysteineresidue in its active site [Gerson et al., 2002; Kaina et al., 2007]. Thus, we used 
the drugs O6-benzylguanine and olaparib to inhibit the repair of the DNA lesions 
produced by MMS. The agent O6-benzylguanine is a potent inactivator of MGMT by 
acting as a substrate for the protein. Specifically, MGMT transfers the benzyl group in 
O6-benzylguanine to the cysteine residue in the active site of the protein resulting in 
MGMT inactivation and, therefore, lesions present at the O6 position of DNA induced by 
MMS remain unrepaired [Dolan et al., 1990 and 1997; Murakami et al., 2007]. First, cells 
were pre-treated with O6-benzylguanine for 4 h before the addition of MMS for an 
additional 4 h. Interestingly, co-treatment of cells with MMS and O6-benzylguanine did 
not appear to increase WRN acetylation (Figure 2.5A, upper panel, compare lines 3 and 
4). Quantitation of data from multiple independent experiments is shown in Figure 2.5B. 
This result suggests that O6-methylguanine lesions are not responsible for triggering 
WRN acetylation.  
 
     Then, we followed a similar strategy as above but using olaparib that inhibits the 
enzyme poly (ADP-ribose) polymerase (PARP) and consequently BER. Olaparib is an 
analog of the substrate NAD+ that binds to the catalytic site of PARP [Plummer et al., 
2006; Lord et al., 2008]. PARP is involved in BER by binding gaps and nicks in DNA 
and helping to open up the damaged DNA to allow access to other components of the 
repair process [Petrucco et al., 2003]. Specifically, olaparib inhibits PARP by preventing 
its automodification that is necessary for its release from DNA and the recruitment of 
proteins involved in BER [Horton et al., 2005]. Importantly, olaparib is not cytotoxic at 
concentrations necessary to achieve PARP inhibition [Cepeda et al., 2006]. Interestingly, 
co-treatment of cells with MMS and olaparib further increased WRN acetylation (Figure 
2.5C, upper panel, compare lines 3 and 4). The increase in WRN acetylation was not due 
to olaparib treatment since the cells treated with olaparib alone had comparable amounts 
of acetylated WRN as control untreated cells (Figure 2.5C, upper panel, compare lines 2  
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Figure 2.5 Correlation between DNA damage and WRN acetylation.  A) 8-D cells 
were incubated in growth medium with or without 40 µM O6-Benzylguanine (O6-BG) for 
4 h followed by incubation with 1 mM MMS for an additional 4 h. For treatment with O6-
BG alone, cells were treated with 40 µM O6-BG for 8 h. Cells were harvested and 
subjected to IP with anti-acetylated lysine antibody and immunobloting with anti-WRN 
antibody (upper panel). 40 ug of each cell lysate were subjected to SDS-PAGE and 
Western blotting with anti-WRN antibody (lower panel). B) Quantitative chart for WRN 
acetylation (mean ± SEM of 3 independent experiments. * = P < 0.05 when compared 
with control untreated cells). C) 8-D cells were incubated in growth medium with or 
without 5 nM Olaparib for 38 h followed by incubation with 1 mM MMS for an 
additional 4 h. For treatment with Olaparib alone cells were treated with 5 nM Olaparib 
for 42 h. Cells were harvested and subjected to IP with anti-acetylated lysine antibody. IP 
products were analyzed by immunoblotting with anti-WRN antibody (upper panel). 60 ug 
of each cell lysate were analyzed by Western blotting with anti-WRN antibody (lower 
panel). D) Quantitative chart for WRN acetylation (mean ± SEM for two independent 
experiments. * = P < 0.05 when compared with control, and # = P < 0.05 when compared 
with cells treated with MMS alone). Lanes 1 in figure A and C are purified acetylated 
WRN (upper panel) or purified unmodified WRN (lower panel) that we used as marker 
(MKR).   
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and 5). Quantitation of data from multiple independent experiments indicates that co-
treatment with MMS and the PARP inhibitor increases WRN acetylation by 4.1 fold, 
compared to a 3.1 fold increase for MMS treatment alone (Figure 2.5D).  These results 
suggest that persistence of 7-methylguanine and 3-methyladenine lesions induce a further 
amplification of WRN acetylation. 
 
      Our previous results show that WRN is acetylated after cisplatin treatment. Cisplatin 
primarily produces bulky DNA adducts repaired by nucleotide excision repair (NER) 
[Sancar et al., 1995; Wang et al., 2001; Zheng et al., 2003]. Therefore, NER-deficient cell 
lines provide opportunities to examine the effects of persistent DNA damage generated 
by cisplatin on WRN acetylation. Experiments were performed by comparing WRN 
acetylation after 19 h cisplatin treatment in NER-proficient (8-D cells, normal NER+) 
and NER-deficient (1-O cells, NER- since they are XPA-deficient) human fibroblasts. As 
shown in Figure 2.6A, WRN acetylation is further amplified in NER-deficient cells after 
cisplatin treatment when compared with NER-proficient cells (upper panel, compare lines 
3 and 5). This increase is not due to a difference in WRN expression levels between the 
cell lines, since a parallel Western analysis of samples using an anti-WRN antibody 
indicated that approximately the same amount of total WRN is present (Figure 2.6A, 
lower panel). In addition, the levels of acetylated WRN in the untreated 1-O and 8-D cell 
lines are comparable (Figure 2.6A, upper panel, compare lines 2 and 4). Quantitation of 
data from multiple independent experiments indicates that WRN acetylation in NER-
proficient cells was higher (2.2 fold) when they are treated with cisplatin as compared to 
their control untreated. However, this difference increases when NER is defective; i.e., 
when NER-deficient cells are treated with cisplatin, the difference was 3.8 fold when 
compared to their untreated control (Figure 2.6B). Therefore, these experiments indicate 
that WRN acetylation corresponds to DNA damage generated by cisplatin and is 
amplified by the persistence of lesions subject to NER. 
 
      To ensure that indeed NER-deficient cells lines have lower efficiency in their DNA 
repair system, and be confident in the correlation that WRN acetylation increases with  
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Figure 2.6 WRN acetylation is amplified as a result of persistent DNA damage.  A) 
8-D (NER+) and 1-O (NER-) cells were incubated in growth medium with or without 25 
uM cisplatin for 19 h before harvest for IP with anti-acetylated lysine antibody. The IP 
products were subjected to SDS-PAGE and Western blotting with anti-WRN antibody 
(upper panel). 60 ug of each cell lysate were subjected to SDS-PAGE and Western 
blotting with anti-WRN antibody (lower panel). Lanes 1 is purified acetylated WRN (upper 
panel) or purified unmodified WRN (lower panel) that we used as marker (MKR).  B) 
Quantitative bar graph for WRN acetylation (mean ± SEM. of 4 independent 
experiments. * = P < 0.05 when compared with control untreated cells, and # = P < 0.05 
when compared with NER Proficient cells treated with Cisplatin). C) To measure 
micronucleus (MN) formation, 8-D cells and 1-O were incubated in growth medium with 
or without 25 uM Cisplatin for 19 h. Cells were washed twice with growth medium and 
cytochalasin B (3 ug/mL) was added to the culture for 24 h. Cells were harvested, fixed 
(methanol:acetic acid 3:1) and stained with a 10% giemsa solution. D) Quantitative bar 
graph for frequency of MN formation in binucleated (BN) cells.   
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persistence of DNA damage generated by cisplatin, we employed the cytokinesis-block 
micronucleus assay that measures genome instability that is a consequence of DNA 
damage. In this technique, genomic instability is scored specifically by counting 
micronuclei that are biomarkers of chromosome breakage and/or chromosome loss, in 
binucleated cells [Fenech et al., 2007 and 2008]. The binucleated appearance of cells is a 
result of blocking cytokinesis with cytochalasin-B, an inhibitor of microfilament ring 
assembly required for the completion of cytokinesis. Trapping cells at this stage 
maximizes detection of chromosome breakage. Higher number of micronuclei is 
indicative of higher chromosome damage. Briefly, NER-proficient and NER-deficient 
cells were incubated with or without cisplatin for 19 h, following incubation with 
cytochalasin-B for 24 h. Cells were harvested, fixed and stained and the number of 
micronuclei formed was scored. The results indicate that, indeed, the NER-deficient cell 
line had higher numbers of micronuclei formed (scoring in Table 2.1) after the cisplatin 
treatment when compared with the NER-proficient cell line (see Figure 2.6C). 
Calculation of the frequency of micronuclei formed in NER-proficient and deficient cell 
lines indicate that cisplatin treatment induces higher levels of micronuclei formation in 
the NER-deficient cells when compared to NER-proficient cells (0.412 vs. 0.227 
micronuclei/binucleated cells, respectively). Quantitation is shown in Figure 2.6D. Thus, 
the increased frequency of micronuclei in NER-deficient cells following cisplatin 
treatment indicates these cells maintain a larger burden of DNA damage and support the 
notion that they are deficient in repair of cisplatin-induced lesions. Collectively, our 
results support the notion that WRN acetylation is amplified as a result of inhibition of 
repair of cisplatin lesions by NER and of 3-methyladeninde and/or 7-methylguanine 
lesions by BER.  
 
Kinetics and cell cycle relationship of WRN acetylation. Lysine acetylation could be 
related to specific cellular responses during the individual cell cycle phases [Huen et al., 
2008]. Therefore, we examined whether WRN acetylation is associated with a particular 
cell cycle phase. Initially, we tried cell cycle synchronization protocols by serum 
starvation and contact inhibition to verify if the levels of WRN acetylation are enriched in 
any specific phase of the cell cycle. However, the purity and amount of cells obtained in  
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CELL LINE TREATMENT BN CELLS 
COUNTED 
# MN 
FOUND 
FREQUENCY 
 
8-D Cells  
(NER Proficient) 
 
- 1000 52 0.052 
8-D Cells 
(NER Proficient) 
25 uM Cisplatin 1000 227 0.227 
1-0 Cells 
(NER Deficient) 
 
- 1000 48 0.048 
1-0 Cells 
(NER Deficient) 
25 uM Cisplatin 1000 412 0.412 
          
Table 2.1 Frequency of MN formation in NER proficient and deficient cell lines. 
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the synchronized populations were not suitable for our purposes. To obtain enriched 
population of cells, we also tried to sort the cells in the different cell cycle phases. 
However, the percentage of recovered cells (especially in G2) was not enough for our 
purposes. Thus, we analyzed and compared the cell cycle profile of a population of 
untreated cells with a population of cells treated with MMS, the treatment that induces 
the highest levels of WRN acetylation. As seen in Figure 2.7, untreated cells showed a 
relatively normal asynchronous profile. However, in MMS treated cells, we can see an 
increase in the percentage of cells at S-phase and a loss of G2/M phase cells. In parallel 
with flow cytometry experiments, acetylated WRN was immunoprecipitated from cells 
using an acetylated lysine antibody and the IP products were subsequently analyzed by 
immunoblotting with an anti-WRN antibody. Again, WRN acetylation increases after the 
MMS treatment, suggesting that WRN acetylation correlated with the increase in S-phase 
cells (Figure 2.7).    
 
     Although the experiments above suggest a correlation between S-phase progression 
and WRN acetylation in vivo, we wanted to corroborate this relationship and investigate 
it further. Thus, to determine if indeed WRN acetylation correlates with S-phase or 
replication blockage, the effect of our treatments on DNA replication was established.  
To this end, the incorporation of bromodeoxyuridine (BrdU) was measured. BrdU is a 
synthetic thymidine analog that is incorporated during DNA synthesis. Experiments were 
performed with cells treated either with or without 1 mM MMS for 4 h or 2 mM HU for 
16 h. BrdU incorporation was measured using the protocol described in the Methods 
section. Interestingly, the incorporation of BrdU was abolished (non-detectable) in HU- 
and MMS-treated cells when compared with untreated cells, indicating that these HU and 
MMS treatments dramatically inhibit DNA replication. Taken together, this evidence 
suggests that acetylation of WRN observed after HU and MMS correlates with blockage 
of replication during S-phase. 
 
     To gain further insight on WRN acetylation in response to induced DNA damage, we 
investigated the kinetics of WRN acetylation to determine the timing of the onset of 
acetylation and the duration of this modification. For these experiments, cells were  
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Figure 2.7 WRN acetylation is associated with S-phase progression.  A) Cells were 
incubated in growth medium with or without 1 mM MMS for 2 h before harvest for 
Hoechst staining. Cells were analyzed by flow cytometry and subsequently subjected to 
immunoprecipitation with anti-acetylated lysine antibody. The IP products were 
subjected to SDS-PAGE and Western blotting with anti-WRN antibody (upper panel). 30 
ug of each cell lysate were subjected to SDS-PAGE and Western blotting with anti-WRN 
antibody (lower panel) to ensure that equal amount of total WRN was present in the IP 
reactions as control. Lanes 1 is purified acetylated WRN (upper panel) or purified 
unmodified WRN (lower panel) that we used as marker (MKR). 
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incubated with MMS (since this treatment produced the highest level of acetylated WRN) 
and harvested at different time points (1 h, 2 h, 4 h). We also analyzed cells 2 h and 4 h 
after MMS treatment (by removing medium containing MMS and replacing it with fresh 
medium). After lysis, acetylated WRN was immunoprecipitated as previously and 
resolved by SDS-PAGE to compare the levels of WRN acetylation at the different time 
points. As seen in Figure 2.8A, WRN acetylation starts to increase gradually after 1 h, 
reaching its maximum level of acetylation after 4 h. However, at a later time, specifically 
4 h after removal of MMS, the levels of acetylated WRN decrease to normal levels 
(quantitation on Figure 2.8B). Thus, the increase in WRN acetylation levels seems to be a 
transient regulatory process for WRN. We also measured the incorporation of BrdU at the 
different time points. Upon treatment with 1 mM MMS, BrdU incorporation dropped to 
29% of the untreated control by 1 h, and to undetectable levels thereafter. Thus, the 
timing of the increase in WRN acetylation after MMS roughly corresponds to its 
inhibitory effect on DNA replication.   
      
Role of HDAC and sirtuins in regulation of WRN acetylation. Modulation of protein 
acetylation depends upon the opposing activities of acetylases and deacetylases. As the 
name implies, deacetylases remove acetyl groups from the side chain of specific lysine 
residues on proteins. Eighteen isoforms of mammalian deactylases have been described 
so far [Walkinshaw et al., 2008]. They have been grouped into two families and four 
classes. The HDAC family, also known as the classical family, is composed of Class I, II 
and IV. The sirtuin family is composed of Class III. The two families have entirely 
different catalytic mechanisms of action and are thus not targeted by the same inhibitor 
molecules [Bieliauskas et al.; 2008; Federico et al., 2011]. Therefore, to establish the role 
of deacetylases in regulation of WRN acetylation, we used inhibitors specific to different 
classes. TSA specifically inhibits Classes I, II and IV by targeting the zinc molecule 
found in the active site of HDACs. Nicotinamide inhibits Class III by binding to the 
conserved pocket of sirtuins that participates in NAD+ cofactor binding and catalysis. 
First, we treated cells with both inhibitors to hinder deacetylases of the different classes 
at the same time and gain knowledge about the dynamics of WRN acetylation. In these  
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Figure 2.8 Kinetics of WRN acetylation.  A) Cells were incubated in growth medium 
with or without 1 mM MMS for 1-4 h before harvest for immunoprecipitation with anti-
acetylated lysine antibody. The IP products were subjected to SDS-PAGE and Western 
blotting with anti-WRN antibody (upper panel). 45 ug of each cell lysate were subjected 
to SDS-PAGE and Western blotting with anti-WRN antibody (lower panel) to ensure that 
equal amount of total WRN was present in the IP reactions as control. For the recovery 
experiments, cells were washed twice with growth medium after 4 h incubation with 
MMS and new medium was added to the culture. Cells were harvested after 2 h or 4 h 
recovery. Lanes 1 is purified acetylated WRN (upper panel) or purified unmodified WRN 
(lower panel) that we used as marker (MKR). B) Quantitative graph for WRN acetylation 
and percentages of BrdU incorporation (N.D. signifies non-detectable).  
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experiments, cells were treated with MMS alone or with MMS and both inhibitors for 4 
h. Interestingly, co-treatment of cells with MMS, TSA and nicotinamide results in a 
further increase of WRN acetylation when compared to cells treated with MMS alone 
(Figure 2.9A, upper panel, compare lines 3 and 4). We also treated cells with HU alone or 
with HU and both inhibitors. Co-treatment with HU, TSA and nicotinamide also resulted 
in a further amplification of WRN acetylation levels when compared to cells treated with 
HU alone (Figure 2.9B, upper panel, compare lanes 3 and 4). The levels of acetylated 
WRN also increased in cells treated with the deacetylase inhibitors alone (Figure 2.9A 
and 2.9B, upper panels, lanes 5). Quantitation of data from multiple independent 
experiments indicates that treatment with both TSA and nicotinamide results in a 5.0 fold 
increase in the levels of WRN acetylation (quantitations showed on Figure 2.9D and E). 
These results suggest that WRN is actively deacetylated in vivo and that acetylation of 
WRN is a dynamic process that, under normal conditions, is at equilibrium through the 
opposing actions of acetyltransferases and deacetylases. At the same time, these results 
also confirm that our immunoprecipitation reactions were pulling down only the 
acetylated form of WRN, since inhibiting deacetylation specifically increased the levels 
of acetylated WRN (Figure 2.9A, B and C, lower panels). 
 
      To investigate the influence of the different classes of deacetylases in WRN 
acetylation levels cells were treated with each of the inhibitors alone. As seen in Figure 
2.9C (compare lanes 2 and 3), TSA alone increased 4.0 fold the levels of acetylated WRN 
(quantitation on 2.9F). However, nicotinamide alone increased 2.0 fold the levels of 
acetylated WRN (compare lanes 2 and 4). Thus, it seems that members of the classical 
HDAC family of deacetylase enzymes contribute more substantially to endogenous WRN 
deacetylation, at least under conditions in which DNA is not damaged.  
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Figure 2.9 Role of HDACs and sirtuins in regulation of WRN acetylation.  A) 8-D 
cells were incubated in growth medium with or without 1 mM MMS, 5 mM 
Nicotinamide (NIC), and/or 10 uM TSA for 4 h before harvest for IP with anti-acetylated 
lysine antibody. IP products were subjected to SDS-PAGE and Western blotting with 
anti-WRN antibody (upper panel). 50 ug of each cell lysate were analyzed by Western 
blotting with anti-WRN antibody (lower panel). B) 8-D cells were incubated  in growth 
medium with or without 2 mM HU, 5 mM NIC, and/or 10 uM TSA for 10 h before 
harvest for IP with anti-acetylated lysine antibody. IP products were subjected to SDS-
PAGE and Western blotting with anti-WRN antibody (upper panel). 30 ug of each cell 
lysate were analyzed by Western blotting with anti-WRN antibody (lower panel). C) 8-D 
cells were incubated in growth medium containing 5 mM NIC and/or 10 uM TSA for 4 h.  
D, E and F) Quantitative bar graphs for WRN acetylation (mean ± SEM of 3 
independent experiments. * = P < 0.05 when compared with control untreated cells, and 
# = P < 0.05 when compared with MMS (in D) or HU (in E) alone.    
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DISCUSSION 
 
     Previous studies have demonstrated that WRN is subject to post-translational 
modification, including phosphorylation, acetylation, and sumoylation. Here, we 
specifically investigate WRN acetylation in further depth. In particular, the dynamics of 
endogenous WRN acetylation and its relationship to DNA damage were examined. We 
found that WRN is acetylated under normal conditions and that acetylation of WRN 
significantly increases after treatment with DNA damaging agents (MMS, MMC, and 
cisplatin) and the replication inhibitor HU, but not after UV. These results are in 
agreement with the relative sensitivity of WS cells to these agents.  WRN is also 
acetylated after treatment with the DNA damaging agent etoposide [Li et al., 2008]. 
Interestingly, the DNA damaging agents that induce WRN acetylation in our studies and 
others are known to produce lesions resulting in strong blocks to replication [Jung et al., 
2007; Liu et al., 2003].  Therefore, our data strongly suggest that WRN may be acetylated 
in response to blockage of replication.  
 
     To establish whether WRN acetylation is actually related to the initial level of DNA 
damage or to a downstream effect of the damage on DNA metabolism, it was relevant to 
consider if increasing the frequency and persistence of DNA damage induced a further 
increase in the levels of acetylated WRN. Thus, we performed a series of experiments in 
which DNA damage removal by standard repair pathways was inhibited after treatments 
with appropriate DNA damaging agents. Initially, we tested the involvement of O6-
methylguanine adducts produced by MMS in inducing WRN acetylation by using O6-
benzylguanine to inactivate MGMT, the enzyme involved in repair of these lesions. 
However, our results showed that O6-methylguanine lesions probably do not result in 
WRN acetylation, since their apparent persistence does not lead to an increase in WRN 
acetylation. To better define if persistence of other lesions produced by MMS results in 
amplification of WRN acetylation, we also targeted BER, which is responsible for repair 
of 7-methylguanine and 3-methyladenine lesions [Wyatt et al., 2006]. BER was inhibited 
with olaparib, which inhibits PARP, the enzyme involved in opening up damaged DNA 
to allow access to other components of the repair process. Our experiments demonstrated 
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an association between persistence of 7-methylguanine and 3-methyladenine lesions and 
WRN acetylation, since we observed a further increase on WRN acetylation when their 
repair was inhibited. It might be possible that the increase in WRN acetylation observed 
after MMS and olaparib co-treatment could be to an inhibition of deacetylases and/or an 
increase in acetylase activity by olaparib. However, our results suggest that this was not 
the case, since the cells treated with olaparib alone had comparable amounts of acetylated 
WRN as control untreated cells. 
 
     There are several possible explanations for the results obtained with the different 
inhibitors. First, it is well established that MMS produces 7-methylguanine at much 
higher frequency than 3-methyladenine and O6-methylguanine, in order of abundance, 
respectively [Lawley et al., 1975; Cloutier et al., 2001; Wyatt et al., 2006; Zhang et al., 
2006; Boysen et al., 2009]. Therefore, it could be difficult to see any changes in WRN 
acetylation caused by O6-methylguanine lesions, since the frequency of these lesions is 
low after MMS and any change in WRN acetylation status could be undetectable. On the 
other hand, MMS and other agents that induce an increase in WRN acetylation levels 
produce lesions that result in blockage of replication [Jung et al., 2007; Liu et al., 2003]. 
Of the lesions formed by MMS, O6-methylguanine disrupts hydrogen bonding with 
cytosine, but otherwise does not alter the double helix to any great extent. Therefore, O6-
methylguanine does not induce replication blockage, instead causing misincorporation 
during DNA replication and giving rise to distinctive G-C to A-T point mutations. If 
indeed WRN acetylation is related to a response to blockage of replication, O6-
methylguanine lesions may not induce amplification of WRN acetylation because they do 
not block replication. The results obtained after inhibition of repair of 7-methylguanine 
and 3-methyladenine lesions agrees with this notion. Several studies suggest that 7-
methylguanine and 3-methyladenine present a strong block to DNA synthesis. 
Methylation at both the N7 and N3 position of purines also destabilizes the N-glycosidic 
bond and renders the modified bases more susceptible to being hydrolyzed into abasic 
sites known to block DNA synthesis [Wyatt et al., 2006; Johnson et al., 2007; O’Connor 
et al., 1988]. In addition, alkylations of the N3 positions of purines, including 3-
methyladenine, block DNA replication directly by occupying the minor groove of DNA, 
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which is normally free of methyl groups [Lindahl et al., 1993]. Thus, based on the 
possible relationship between WRN acetylation and blockage of replication, it is tempting 
to speculate that we observed a further amplification in WRN acetylation upon 
persistence of 7-methylguanine and 3-methyladenine because of increased frequency of 
encounters of replication forks with those lesions in the DNA template that, in turn, more 
often block DNA replication.  
 
     Although we focused primarily on MMS treatment because it elicited the largest 
increase in WRN acetylation, we also wanted to know if the induction and/or persistence 
of the lesions caused by other agents used in our initial experiments also increased WRN 
acetylation. Thus, we also compared the effect of bulky, covalent DNA adducts generated 
by cisplatin in cells deficient or proficient for NER, the repair pathway responsible for 
removing the majority of lesions induced by cisplatin. The results of those experiments 
demonstrated that cisplatin treatment of NER-deficient cells induced a further increase in 
the levels of WRN acetylation when compared with normal NER-proficient cells. 
Furthermore, the chromosome instability caused by cisplatin treatment (measured using 
the micronucleus assay) suggests that cisplatin lesions are likely to cause replication fork 
blockage and collapse.  These results using strategies to inhibit DNA repair lead to 
several conclusions. First, WRN acetylation can be directly correlated with DNA damage 
induced by these agents, instead of some non-specific effect of the agent on some other 
aspect of cellular metabolism or physiology. Second, the increase in WRN acetylation 
response to repair inhibition indicates that is not the induction but the persistence of 
damage. Importantly, our data is consistent and extent previous studies showing WRN 
acetylation after DNA damage [Blander et al., 2002; Li et al., 2008; Muftuoglu et al., 
2008]. Here, we took a step further and established (for the first time) a relationship 
between WRN acetylation and persistence of DNA damage.  
 
     In this study, we have demonstrated that WRN acetylation is a dynamic process. 
Specifically, we have shown that there is a time-dependent increase of WRN acetylation, 
reaching the maximum levels within 4 h after MMS treatement. These results are in 
agreement with previous studies showing temporal increase on WRN acetylation levels 
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after etoposide treatment [Li et al., 2008]. Interestingly, our flow cytometry analysis after 
MMS treatment indicates that the increase in the levels of acetylated WRN correlates to 
an increase in the percentage of S-phase cells. In light of these findings, it was relevant to 
consider if WRN acetylation has a relationship to DNA replication. Thus, the 
incorporation of BrdU was measured after HU and MMS treatments.  Interestingly, HU 
and MMS treatments markedly decreased the levels of BrdU incorporation. Since WRN 
acetylation increased in response to HU and MMS treatments, our results indicate that 
WRN acetylation correlates with inhibition of DNA synthesis. Further, our findings 
strongly suggest that WRN acetylation observed after DNA damaging agents and 
replication blocking agents might arise as a response to DNA damage-induced replication 
stress.    
 
     Since the acetylation state of WRN is influenced by acetylases and deacetylases, we 
inhibited the groups of deacetylases to study their role in regulation of WRN acetylation. 
For those experiments, we used the drugs TSA and nicotinamide in order to inhibit 
various deacetylases between the different classes of deacetylases that exist in humans. 
The result of those experiments revealed that, even in the absence of DNA damaging 
treatments, deacetylase inhibitors amplified the levels of WRN acetylation by five fold. 
This result indicates that WRN acetylation state is determined by equilibrium between 
acetylation and deacetylation. Thus, disruption of this equilibrium, in this case through 
the inhibition of deacetylases, results in a shift towards increased WRN acetylation. 
These experiments also suggest that another scenario for amplification of WRN 
acetylation levels in response to DNA damage might be a change in the balance between 
acetylases and deacetylases. Our results suggest that DNA damage shifts the balance 
towards acetylation and perhaps increased acetylase or decreased deacetylase activity. 
Thus, the status of WRN acetylation might be regulated further by the presence of 
specific proteins involved in the acetylation process, which might favor specific 
acetylated or deacetylated forms of WRN.  
 
     We also studied the role of the different classes of deacetylases in regulation of WRN 
acetylation. To date, the classes have been divided into two families and our results 
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indicate that members of both families contribute to WRN deacetylation. In our studies, 
Class I, II and IV, that are the members of the HDAC family, appear to play a larger role, 
since TSA resulted in higher levels of WRN acetylation when compared to nicotinamide 
alone.  These results indicate, for the first time, that acetylated forms of WRN are 
substrates for the Class I, II and IV of histone deacetylase enzymes. However, sirtuins 
(Class III) also play some role in regulation of WRN acetylation, since nicotinamide 
treatment alone at least doubled the amount of acetylated WRN when compared with 
untreated cells. The latter results are in agreement with recent studies showing interaction 
and regulation of WRN by sirtuins. Specifically, recent studies have shown that: 1) WRN 
interacts with SIRT1 both in vitro and in vivo and is hypoacetylated in cells 
overexpressing SIRT1 [Law et al., 2009; Li et al., 2008], 2) sirtuin deacetylase activity 
protects WRN from ubiquitination and sequential degradation by the 26S proteosome 
[Kahyo et al., 2008, Li et al., 2010], 3) SIRT6 collaborates with WRN at telomeric 
chromatin [Michishita et al., 2008], and 4) SIRT1 deacetylation regulates WRN helicase 
and exonuclease activity (see Figures 3.2 and 3.3 in Chapter 3). In addition, our results 
are consistent with studies showing WRN regulation in response to deacetylase 
inhibitors. Specifically, in response to TSA treatment, WRN translocates from the 
nucleolus to nucleosplasmic foci, a movement that correlates with WRN acetylation 
[Blander et al., 2002; Karmakar et al., 2005]. A recent study identified six lysine residues 
(K366, K887, K1117, K1127, K1389, and K1413) that are subject to acetylation on 
ectopically expressed, acetylated WRN [Li et al., 2010]. Thus, different deacetylases 
might target different acetylated lysine sites on WRN. More research needs to be done to 
determine which deacetylases are responsible for removing acetyl groups from individual 
lysines. 
  
     In summary, we report here that DNA damage and replication blocking agents induce 
WRN acetylation. Our results support the view that WRN is acetylated in response to 
blockage of replication. Cell cycle analysis, BrdU incorporation assays, and the effect of 
persistent DNA damage results are consistent with this possibility. Our findings regarding 
WRN regulation by deacetylases show for the first time that deacetylation of endogenous 
WRN is influenced by not only sirtuins but also HDACs. Since acetylation of WRN is a 
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transient process, we speculate that modification of WRN is used as a rapid way to 
respond to cellular stress. Collectively, our study has identified a crucial process by 
which WRN is regulated in response to DNA damage and blockage of replication. These 
results are in agreement with its putative role in DNA metabolism and maintenance of 
genome stability.  
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CHAPTER III 
 
WRN ACETYLATION REGULATES ITS ENZYMATIC ACTIVITIES 
 
INTRODUCTION 
 
     The amino acid sequence of WRN revealed several functional domains including its 
identification as a member of the RecQ family of helicases. To date, several laboratories 
have overproduced and purified recombinant wild type and mutant WRN proteins to 
characterize their catalytic activities and properties. As expected from its strong 
homology to RecQ helicases, WRN’s central region confers ATPase activity that 
provides the energy for unwinding DNA with a 3’→5’ directionality [Gray et al., 1997; 
Suzuki et al., 1997; Shen et al., 1998; Chen et al., 2002].   Furthermore, the existence of 
an N-terminal RNase D-type domain, not present in any other human RecQ member, 
confers to WRN an intrinsic 3’→5’ exonuclease activity [Huang et al., 1998; Shen et al., 
1998b; Mian et al., 1997]. Interestingly, the exonuclease and helicase activities of WRN 
have been shown to be physically and functionally separable [Huang et al., 1998]. How 
these functions are coordinated during DNA metabolism is unknown. However, what is 
well-known is that both activities (helicase and exonuclease) of WRN occur 
preferentially on complex DNA structures, such as those formed during replication and 
recombination, including forks, bubbles, and Holliday junction intermediates 
[Constantinou et al., 2000; Brosh et al., 2001; Mohaghegh et al., 2001; Lebel et al., 1999; 
Orren et al., 2002; Opresko et al., 2004].  The unwinding activity also disrupts unusual 
DNA structures such as G-quartets and triplexes [Brosh et al., 2001; Johnson et al., 
2010]. In addition, WRN possesses DNA binding activity that appears to be dependent 
upon DNA structure with no apparent nucleotide sequence preference [Orren et al., 1999; 
Brosh et al., 2002]. The affinity of both the helicase and exonuclease for alternative DNA 
structures might reflect their roles in resolving specific DNA intermediates that might 
form during DNA metabolism.  
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     Just downstream of the helicase domain there are additional sequences in WRN 
typical of some RecQ members, known as the RecQ-conserved (RQC) and the Helicase 
and RNase D C-terminal (HRDC) domains. These domains fold into distinct structural 
entities and have DNA binding affinities [Liu et al., 1999; von Kobbe et al., 2003; Hu et 
al., 2005; Lee et al., 2005].  In fact, experiments using truncated versions of WRN have 
shown that it possess four distinct DNA binding regions, including the helicase, RQC and 
HRDC domains [von Kobbe et al., 2003]. The exonuclease domain also possesses DNA 
binding affinity [Machwe et al., 2006].   
 
     WRN deficiency causes replication abnormalities and hypersensitivity to agents that 
severely inhibit replication fork progression, suggesting that WRN might participate in 
resolution of replication blockage. It has been proposed that the first step in dealing with 
a blocked replication fork involves its regression. This process occurs through re-
annealing of the parental strands and pairing of the daughter strands to generate a 
Holliday junction structure or “chicken foot intermediate” [Haber et al., 1999; Cox et al., 
2002]. Fork regression would be facilitated by an enzyme that possesses both unwinding 
and strand annealing activity. Interestingly, similar to some recombination proteins, 
WRN also facilitates the pairing of complementary DNA strands, this annealing activity 
works in concert with its helicase activity to perform strand exchange and regress model 
replication forks [Machwe et al., 2005; Machwe et al., 2006]. The latter suggests that 
WRN, as part of its role in a genome maintenance pathway, might be involved in the 
correct resolution of intermediates that arise from blocked replication forks in vivo, 
caused by DNA damage.  Thus, the genomic instability of WRN-deficient cells may be 
due to an inability to complete normal DNA replication in the absence of functional 
WRN. 
    
      The enzymatic activities of WRN on DNA substrates have been shown to be 
modulated by post-translational modifications [Kusumoto et al., 2007].  Specifically, its 
helicase and exonuclease activities are regulated by phosphorylation [Karmakar et al., 
2002; Yannone et al., 2001; Cheng et al., 2003]. Importantly, WRN is subject to post-
translational modifications following DNA damage. These modifications correlate with 
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WRN nuclear re-localization to replication foci, a likely site for WRN function in DNA 
metabolism [Blander et al., 2002; Cheng et al., 2003; Pichierri et al., 2003; Woods et al., 
2004; Karmakar et al., 2005].  Collectivelly, these studies suggest that it is likely that 
cellular WRN trafficking and function is regulated by protein modification, and perhaps 
may be related to a specific DNA damage response pathway.   
 
     Our studies have demonstrated that genotoxins induce WRN acetylation (see chapter 
II). In order to further understand the effect of WRN acetylation on its biochemical 
function, unmodified WRN, acetylated WRN and deacetylated WRN protein (expressed 
in and purified from HEK293 cells) were compared as to their helicase, exonuclease, and 
fork regression activities on relevant DNA structures, with particular emphasis on WRN 
action on model replication forks. In this chapter, we report that acetylated WRN has 
significantly less exonuclease and helicase activities than unmodified WRN on simple 
DNA substrates (partial DNA duplexes). Interestingly, deacetylation of WRN at least 
partially restored the normal level of exonuclease and helicase activities. When a more 
rigorous examination was done on more complex DNA substrates including replication 
forks, surprisingly, the effect of acetylation on WRN fork regression activity was much 
less pronounced. Importantly, we provide evidence that the exonuclease activity of 
unmodified and acetylated WRN on model replication forks is comparable. Together, 
these experiments suggest that WRN acetylation helps to regulate WRN specificity by 
reducing its preference for non-physiological substrates.  
       
RESEARCH DESIGN  
 
SPECIFIC AIM: To investigate the effect of WRN acetylation on its biochemical 
functions   
 
RATIONALE 
 
      Our previous studies demonstrate that WRN is acetylated after treatment of cells with 
DNA damaging agents, particularly those that block replication fork progression. It has 
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been shown that phosphorylation of WRN after treatment with DNA damaging agents 
decreases its exonuclease and helicase activities [Karmakar et al., 2002; Yannone et al., 
2001; Cheng et al., 2003], indicating that WRN modification might alter its catalytic 
activities. However, it is unclear if acetylation alters WRN catalytic activities. To this 
end, we analyzed in detail how WRN acetylation influences its catalytic activities. 
Specifically, unmodified and acetylated WRN were compared as to their helicase, 
exonuclease and fork regression activities. Initially, unmodified WRN was directly 
compared to acetylated WRN or deacetylated WRN on simple DNA partial duplexes in 
regard to their helicase and exonuclease activities. Since WRN has higher specificity for 
complex DNA substrates, such as those form during DNA replication and recombination 
(including Holliday junction and forks), we also studied the fork regression and 
exonuclease activities on model replication forks and Holliday junctions. A mutant WRN 
protein containing lysine to arginine mutations at conserved acetylation sites which 
cannot be acetylated was analyzed, to determine if indeed WRN acetylation sites are 
required for WRN catalytic activities.  
 
METHODS  
 
Production and purification of unmodified and modified wild-type and mutant 
FLAG-WRN proteins. FLAG-tagged unmodified, acetylated, deacetylated, and mutant 
WRN proteins were overexpressed in HEK293 cells using a transient transfection assay 
(performed in the laboratory of our collaborator, Dr. Jianyuan Luo, University of 
Maryland Medical School). Unmodified FLAG-WRN and acetylated FLAG-WRN were 
expressed and purified as described previously (see methods section in Chapter II). To 
produce the FLAG-WRN 6KR mutant, site-directed mutagenesis was used to convert 
lysine residues (K366, K887, K1117, K1127, K1389, and K1413) to arginine.  
  
DNA substrate construction. Oligonucleotides were purchased from Integrated DNA 
Technologies and their sequences are given in table 3.1. Each substrate was generated by 
radiolabeling the 5’ end of one strand (depicted in each figure) with [ɤ-32P] ATP and T4 
polynucleotide kinase followed by annealing with a two-fold excess of one or more 
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unlabeled complementary strand(s). Annealed substrates were separated by native PAGE 
(12%), excised, and extracted. Labeled oligomers and annealed duplex substrates were 
then purified using a gel extraction kit (Qiagen).  
      
     The forks were constructed by radiolabeling one oligomer (the specific oligomer used 
is depicted in each figure) with [ɤ-32P] ATP and T4 polynucleotide kinase, 3’-
phosphatase free (Roche Molecular Biologicals, Indianapolis, IN). In an initial annealing 
step to form parental daughter partial duplexes, labeled strand was heated to 90°C and 
slow-cooled with excess complementary unlabeled daughter strand, while the other 
unlabeled parental strand was treated similarly in individual reactions with excess of its 
complementary daughter strand. The resulting lagging and leading parental-daughter 
partial duplexes were then mixed together at 37°C for 18 h. After separation by native 8% 
PAGE, the substrate was excised, extracted into TEN buffer (10mM Tris, pH 8.0, 1 mM 
EDTA and 10 mM NaCl), and stored at 4°C prior to use. 
 
Helicase and Fork Regression Assays. To measure enzyme-catalyzed unwinding, the 
DNA substrates were incubated without or with unmodified, acetylated and deacetylated 
FLAG-WRN proteins (as indicated in figures) in WRN reaction buffer [40 mM Tris-HCl, 
pH 8.0, 4 mM MgCl2 (unless otherwise indicated), 1 mM ATP (or 0.25 mM when 
indicated), 0.1% Nonidet P-40, 0.1 mg/ml bovine serum albumin (BSA), and 5 mM 
dithiothreitol] at 37°C for the specified times. Reactions were subsequently incubated 
with Proteinase K (1 mg/ml), SDS (0.2%) and EDTA (5 mM) for 30 min (or 1 h when 
indicated) at 37°C and then stopped by addition of one-sixth volume of loading dyes 
(30% glycerol, 0.25% bromphenol blue, 0.25% xylene cyanol, and 50 mM EDTA). 
Samples were subjected to electrophoresis in an 8% native polyacrylamide gel in 1X Tris 
borate-EDTA at 100 V for 3 h at room temperature. The gel was vacuum-dried at 80°C 
for 1 h, and radioactive DNA products were visualized by phosphorimaging.  
 
Exonuclease Assays. Exonuclease reactions (10 µl) containing the substrate of interest 
and FLAG-WRN proteins (at the indicated concentrations) in WRN reaction buffer 
without, or with 1 mM ATP (when indicated in figures), were preincubated on ice for 5 
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min, and then transferred to 37°C for the indicated times. Reactions were stopped by the 
addition of formamide loading buffer (95% formamide, 20 mM EDTA, 0.1% bromphenol 
blue, and 0.1% xylene cyanol). DNA products were heated at 90°C and separated by 
denaturing (14%) PAGE. Digestion of the labeled strand by the 3’ to 5’ exonuclease 
activity of WRN proteins was visualized by phosphorimaging. 
 
RESULTS 
 
Acetylation alters WRN biochemical activities and specificity. Our results 
demonstrated that WRN is acetylated in response to DNA damaging agents and 
replication blocking agents. To further understand the function of WRN in DNA 
metabolism, we analyzed in detail how WRN acetylation influences its catalytic 
activities. Using the protocol depicted in Figure 3.1A, unmodified FLAG-WRN, 
acetylated FLAG-WRN and deacetylated FLAG-WRN were made from HEK293 cells. 
Western blot techniques were used to determine their protein levels and confirm the 
acetylated state (Figure 3.1B). First, these proteins were used to perform a helicase assay 
on a 21-bp partial duplex with a 49-nt 3’ overhang structure constructed by annealing 
oligomers 21-lag and 70-lag.  (Figure 3.2A, for details; see “Methods” section and Table 
3.1 for nucleotide sequences). We started out using this kind of substrate, with one blunt 
end and the other end with a 3’ single-stranded region, because the helicase activity of 
WRN requires a 3’ single-stranded DNA region relative to the duplex DNA to be 
unwound. Using equivalent protein concentrations, acetylated FLAG-WRN showed 
significantly less helicase activity than FLAG-WRN (Figure 3.2B, lanes 5-7 vs. lanes 2-
4). Interestingly, deacetylation of WRN almost completely restored the normal level of 
helicase activity (Figure 3.2B, lanes 8-10 vs. lanes 5-7). A quantitative graph for WRN 
unwinding activity is presented in Figure 3.2C. Thus, acetylation appears to suppress 
WRN helicase activity on simple partial duplexes.  
  
     Using the same proteins, exonuclease assays were performed on different partial 
duplex substrates with a recessed 3’-end structure (see structures in Figure 3.3), to 
determine the effect of acetylation on WRN exonuclease activity. These substrates with  
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Figure 3.1 WRN acetylation assay. A) To obtain unmodified FLAG-WRN, cells were 
transfected with vector specifying production of FLAG-WRN. To obtain acetylated 
WRN, cells were co-transfected with individual vectors specifying production of FLAG-
WRN and CMV-p300 or CMV-CBP (two acetyltransferases that acetylate WRN in vivo 
[Li et al., 2010]).  To obtain deacetylated FLAG-WRN, cells were co-transfected with 
FLAG-WRN, CBP (since it is the major acetylase involved in WRN acetylayion [Li et 
al., 2010]) and SIRT1 (a histone deacetylase) vectors. Cells were harvested 36 h after 
transfection and were lysed in a FLAG-lysis buffer. After anti-FLAG M2 
immunoprecipitation, the immobilized FLAG-WRN proteins were released using FLAG 
peptide and purified unmodified or acetylated FLAG-WRN was collected. To confirm 
that the system works and determine protein concentration and the level of acetylation, 
the purified FLAG-WRN proteins were resolved by SDS-PAGE and detected by western 
blot. B) For each transfection strategy, WRN was produced (lower panel). In the case of 
cotransfection with p300 or CBP, acetylated WRN was produced (upper panel, lane 2), 
and in the case of cotransfection with p300 and SIRT1, the levels of acetylated WRN 
were dramatically reduced (upper panel, lane 3). 
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Table 3.1  
Oligonucleotides used to construct DNA substrates 
_______________________________________________________________________________ 
21-lag   
GAGGATATCATGTACGATAGCP 
 
21- lead 
GCTATCGTACATGATATCCTCP 
 
K21RP3   
TAGGGTTAACATCAAGTCACGP 
 
30-lead 
GCTATCGTACATGATATCCTCACACTCACT 
 
32-lag 
ATTCAGAGTGTGAGGATATCATGTACGATAGCP 
 
G35left 
AGCTCCTAGGGTTACAAGCTTCACTAGGGTTGTCC 
 
3(52)scr 
CACTCCTCTGAGTCTGGACGGCAGCTGGCCAAGTGTGAGTGTGAGTGTGAGT 
 
5’(52) 
TCACTTGACAAGTGACTGTGACCTAGGCATCCTCCAGTTCCTGGAGTCAGTG 
 
70-lag  
GCTATCGTACATGATATCCTCACACTCTGAATAGCCGAATTCTTAGGGTTAGGGTTAACATCAAGTCACGP 
 
70 lead 
CGTGACTTGATGTTAACCCTAACCCTAAGAATTCGGCTTAAGTGAGTGTGAGGATATCATGTACGATAGC 
 
K70P3 
CGTGACTTGATGTTAACCCTAACCCTAAGAATTCGGCTTAAGTGAGTGTGAGGATATCATGTACGATAGCP 
 
K70left fork 
CAGCAACATACATTGTAAGAGCATACAGACACGCACGAATTCTTAGGGTTAGGGTTAACATCAAGTCACGP 
 
K70right fork 
GCTATCGTACATGATATCCTCACACTCACTTAAGCACTCAGGCACTCTAGCTCTGCTCACGACCAGACATP 
 
C80 
GCTGATCAACCCTACATGTGTAGGTAACCCTAACCCTAACCCTAAGGACAACCCTAGTGAAGCTTGTAACCCTAGGAGC
TP 
 
*base 
CACTGACTCCAGGAACTGGAGGATGCCTAGGTGGCCAGCTGCCGTCCAGACTCAGAGGAGTG 
 
HJ70M8-1 
GCTATCGTACATGATATCCTCACACTCACTTAAGCCGAAGAGAATCCTGATCTCAATTGTAGTTCAGTGCP 
 
HJ70M8-2 
GCACTGAACTACAATTGAGATCAGGATTCTCTTCGGCTTCTCATTCACACTCCTATAGTACATGCTATCGP 
 
HJ70M8-3 
CGATAGCATGTACTATAGGAGTGTGAATGAGAAGCCGAATTCTTAGGGTTAGGGTTAACATCAAGTCACGP 
 
All sequences are depicted in 5’ to 3’ orientation 
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Figure 3.2 WRN helicase activity is regulated by acetylation. A) Substrate containing 
the 3’ overhang constructed by annealing oligomers 21-lag and 70-lag. The relative 
position and size of the complementary region (21 bp) is indicated. B) Helicase assay was 
performed with 21-bp partial duplex using FLAG-WRN, acetylated FLAG-WRN, and 
deacetylated FLAG-WRN produced as explained in figure 3.1. The 3’ overhang (5 fM) 
was incubated at 37°C for 10 min with FLAG-WRN proteins (80, 160, and 320 pM) and 
analyzed as described in the Methods section. C) Graphic representation for WRN 
unwinding activity (mean and S.D. for three independent experiments).   
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one blunt end and the other end with a recessed 3’ end were selected for our initial 
studies because they are resistant to the helicase activity of WRN (the helicase activity 
requires a 3’ single-stranded region).  Therefore, when WRN is added to these substrates, 
the exonuclease activity is directed to the recessed end (Figure 3.3A).  Exonuclease 
activity at the 3’ end of the labeled strand is measured by the appearance of shorter 
fragments on a denaturing gel.  As expected, WRN degrades the 3’-end of the labeled 
strand in a step wise manner in a 3’ to 5’ direction (Figure 3.3B, lines 2-4). Interestingly, 
acetylation of WRN markedly decreased its exonuclease activity (Figure 3.3B, lanes 5-7 
vs. lanes 2-4). Again, deacetylation of WRN can reverse this effect (Figure 3.3B, 
compare lanes 8-10 vs. lanes 5-7). An eight fold molar excess of acetylated WRN is 
needed to obtain similar exonuclease activities between unmodified and acetylated WRN 
on this recessed 3’ end substrate (Figure 3.3C, compare lines 2-4 to 5-7). Although an 
ATP requirement is connected with unwinding and the exonuclease activity of WRN is 
not ATP-dependent, several laboratories have shown that WRN exonuclease activity is 
stimulated by ATP hydrolysis on certain substrates [Kamath-Loeb et al., 1998; Machwe 
et al., 2002; Shen et al., 2000; Brosh et al., 2001]. Thus, we added ATP to the 
exonuclease reactions to investigate if ATP can stimulate the exonuclease activity of 
acetylated WRN. However, the exonuclease activity of acetylated WRN was not 
significantly stimulated even in the presence of ATP (Figure 3.3D, lane 2 vs. 3). 
Collectively, these results indicate that acetylation decreases WRN exonuclease activity 
on simple partial duplex substrates.  
 
     It is well known that WRN prefers special DNA structures, such as those formed 
during replication and recombination, including forks [Opresko et al., 2003].  
Importantly, WRN coordinates its annealing activity with its helicase activity to perform 
strand exchange and regress model replication forks [Machwe et al., 2005; Machwe et al., 
2006]. The latter support the notion that WRN might be involved in the correct resolution 
of intermediates that arise from blocked replication forks in vivo, caused by DNA 
damage. Therefore, we wanted to explore the effect of WRN acetylation on more 
complex structures. To this end, a more rigorous examination was done by comparing the  
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Figure 3.3 WRN exonuclease activity is regulated by acetylation. A) WRN 
exonuclease directionality is defined as 3’ to 5’ with respect to the direction that the 
single strand of the DNA substrate is degraded, as despicted in the figure. Exonuclease 
activity at the 3’ end of the labeled strand is measured by the appearance of shorter 
fragments on a denaturing gel.  B) Time course of the exonuclease activities of FLAG-
WRN proteins on a 35-bp partial duplex with a recessed 3’ end probe (0.1 nM), 
constructed by annealing oligomers G35left and C80, at 37°C were compared. C) The 
time course exonuclease activities of unmodified FLAG-WRN and 8-fold molar excess 
of acetylated FLAG-WRN protein on a 3’-end probe (0.1 nM) constructed by annealing 
oligomers 30-lead and K70P3. D) Reactions containing 3’ end probe (0.1 nM) 
constructed by annealing oligomers 30-lead and K70P3 with or without ATP (1 mM), as 
indicated, were incubated at 37°C for 15 min.  
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unwinding strength and fork regression activities of unmodified and acetylated WRN on 
a series of DNA substrates constructed using the same labeled strand. Briefly, a labeled 
80-nt strand was annealed with different unlabeled complementary strands to produce a 
3’ overhang structure, a 2-stranded fork, a 3-way junction and a model 4-stranded 
replication fork as well as a Holliday junction structure (see structures in Figure 3.4A and 
3.5A) that were subsequently purified. The common labeled strand made it 
straightforward to use precisely the same molar amounts of these DNA substrates to 
facilitate direct comparison in enzymatic assays. For these assays, these substrates were 
incubated in WRN-reaction buffer containing unmodified or acetylated WRN. As shown 
in figure 3.4A and B, unmodified WRN unwinds the 2-stranded fork (compare lines 5 
and 6) and the 3-way junction (compare lines 8 and 9) with higher efficiency than 
acetylated WRN, in order of preference, respectively. As expected, the 3-way junction 
was unwound to a variety of products that were included in the calculation. We further 
tested a series of 3-way junction with different sequences on the 3’-flap and, consistent 
with these results, acetylated WRN was less efficient than unmodified WRN (data not 
shown). The difference between unmodified and acetylated WRN unwinding activities 
was less dramatic on the 3’ overhang substrate (compare lines 2 and 3). Unwinding of the 
Holliday junction substrate was not detected (data not shown), likely because of the 
length of the duplex regions of this substrate. In contrast, unmodified and acetylated 
WRN have comparable fork regression activity (Figure 3.4A, compare lines 11 and 12). 
In parallel, we measured the exonuclease activities of unmodified and acetylated WRN 
on the same substrates. Similar to previous results, the exonuclease activity of 
unmodified WRN was stronger than the exonuclease activity of acetylated WRN on the 
3’ overhang (Figure 3.5A, compare lines 2 and 3) and the 2-stranded fork (compare lines 
5 and 6). However, the exonuclease activities of unmodified and acetylated FLAG-WRN 
were comparable on the 3-way junction (compare lines 8 and 9) and the model replication 
fork (compare lines 14 and 15).  On the Holliday junction (compare lines 11 and 12), 
unmodified WRN appeared to be slightly mor active than acetylated WRN. A 
quantitative chart for WRN exonuclease activity on the different substrates is presented in 
Figure 3.5B. Taken together, these results suggest that acetylation of WRN alters its 
specificity for certain types of substrates.  
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Figure 3.4 Acetylation regulates WRN specificity. A)  A labeled 80-nt strand (K70P3 
oligomer) was annealed with different unlabeled complementary strands to produce a 3’ 
overhang structure (K21RP3 oligomer + K70P3 oligomer), a 2-stranded fork (K70left 
fork oligomer + K70P3 oligomer), and a 3-way junction (K70left fork oligomer + 
K70right fork oligomer + K70P3 oligomer).  The model replication fork was generated 
by annealing parental daughter partial duplexes (labeled K70P3 + unlabeled 21-lead 
oligomer and unlabeled 70-lag + excess 32-lag oligomer). After individual substrates 
were gel-purified, these substrates (0.1 fm) were incubated at 37°C for 1 h in WRN-
reaction buffer containing unmodified or acetylated WRN and analyzed as described in 
the Methods section. B) For experiment in A, percent of unwinding/regression was 
calculated (mean and S.D. for four independent experiments).  
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Figure 3.5 Acetylation regulates the specificity of WRN exonuclease activity. A)  The 
substrates constructed using the same labeled 80-nt strand (as described in Figure 3.5A) 
were incubated at 37°C for 1 h in WRN-reaction buffer containing unmodified or 
acetylated WRN and analyzed as described in the Methods section. The Holliday junction 
was constructed by annealing of the labeled K70P3 oligomer with unlabeled partial 
complementary strands (HJ70M8-1 oligomer + HJ70M8-2 oligomer + HJ70M8-3 
oligomer).  B) For experiment in A, percent reduction of full length labeled strand by 
WRN exonuclease activity was calculated.  
 
63 
 
     To confirm that unmodified and acetylated WRN have comparable fork regression 
activities, a different model replication fork was designed (see Figure 3.6A for details) 
and the fork regression activities of unmodified WRN and acetylated WRN were 
compared over a range of concentrations. Again, the difference in fork regression activity 
was much less pronounced, as manifested specifically by daughter duplex formation that 
is a diagnostic of fork regression (Figure 3.6B, lines 2-4 vs. 5-7). However, they have 
minor differences in the generation of other products that result from the helicase and 
exonuclease activities of WRN. After these interesting results we analyzed the 
exonluclease activity of WRN on this substrate. Interestingly, unmodified and acetylated 
WRN showed similar efficiency in exonuclease degradation of the labeled strand of this 
fork substrate (Figure 3.6C, lanes 2-4 vs. 5-7). Together, these results suggest that 
unmodified and acetylated WRN have comparable activities on four-stranded replication 
forks. 
  
     Recently, lysine residues subject to acetylation were identified after performing a 
mass spectrometry analysis of purified ectopically expressed acetylated WRN (obtained 
after co-transfection of FLAG-WRN with the acetylases CBP and p300 in HEK293 cells) 
[Li et al., 2010]. According to that study, the acetylated lysine residues in WRN are 
K366, K887, K1117, K1127, K1389, and K1413. Thus, as a negative control, we studied 
a WRN mutant containing all six lysines mutated to arginine, a conservative basic amino 
acid substitutions that cannot be acetylated, to examine whether any of these residues are 
required for WRN enzymatic function. In these experiments, the helicase and 
exonuclease activities of unmodified FLAG-WRN and the 6KR mutant were compared 
on simple partial duplexes substrates. To amplify the inherent exonuclease activity of 
WRN, certain reactions were carried out using Mn2+ instead of Mg2+ as a co-factor. As 
shown in Figure 3.7A and B, the WRN 6KR mutant maintains similar activities as the 
wild type (unmodified) WRN under the conditions used, suggesting that the arginine 
substitutions do not directly affect WRN enzymatic properties or the folding of the 
protein.    
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Figure 3.6 Effects of WRN acetylation on a model replication fork. A)  A model 
replication fork was constructed containing homologous leading and lagging arms with 
five nucleotides of heterology at the fork junction to prevent spontaneous branch 
migration.  Regression the fork is determined specifically by daughter duplex formation 
which requires unwinding and pairing of the physically unlinked daughter strands. B) 
Equal and increasing amounts of unmodified and acetylated WRN were assayed for fork 
regression activity on the replication fork model (4 pM) and analyzed as described in the 
Methods section. C) Exonuclease activities of unmodified and acetylated FLAG-WRN 
proteins on the model replication fork over 30 min at 37°C in WRN reaction buffer 
(including 1 mM ATP).  DNA products were separated by denaturing (14%) PAGE and 
visualized by phosphorimaging. 
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Figure 3.7 WRN 6KR-mutant retains similar activities as the WRN-wt. A) Helicase 
assay was performed with a partial duplex, containing a 31 and 21 nt 5’ and 3’ single-
stranded arms (constructed by annealing oligomers 3(52)scr and *base), using FLAG-
WRN (WRN-wt) and the FLAG-6KR-mutant (WRN 6KR) produced as explained in the 
Methods section. The partial duplex was incubated at 37°C for 30 min with FLAG-WRN 
proteins in WRN reaction buffer (including 1 mM MgCl2 or 1 mM MnCl2, as depicted, 
and 0.25 mM ATP) and analyzed by native PAGE. B) Exonuclease activities of 
unmodified and 6KR-mutant FLAG-WRN proteins on a partial duplex (constructed by 
annealing oligomers 5’ (52) and *base) over 20 min at 37°C in WRN reaction buffer 
(including 1 mM MnCl2 instead of MgCl2 when indicated).  DNA products were 
separated by denaturing (8%) PAGE and visualized by phosphorimaging. 
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DISCUSSION 
 
     The genomic instability and hypersensitivity to DNA damaging agents of WS cells are 
thought to be caused by DNA metabolic defects that result from absence of WRN 
function. This notion has been supported by the identification of 3’→ 5’ helicase and 
3’→ 5’ exonuclease activities of WRN. Notably, WRN has been reported to possess 
strand annealing and strand exchange activities. Most recently, this notion has been 
strengthened by the discovery of a new activity in WRN, when Machwe et al. reported 
that WRN regresses model replication forks [Machwe et al., 2006]. Collectively, these 
biochemical properties of WRN suggest that it has an important role in DNA metabolism. 
Interestingly, the enzymatic activities of WRN on DNA substrates have been shown to be 
modulated by phosphorylation [Karmakar et al., 2002; Yannone et al., 2001; Cheng et al., 
2003]. However, how WRN activities are regulated by acetylation remain to be 
elucidated. In this study, we report the impact of acetylation on WRN catalytic activities 
using helicase, exonuclease, and fork regression assays.  
 
     Initially, WRN helicase and exonuclease activities of unmodified and acetylated WRN 
were compared using simple DNA partial duplexes structures. Our experiments clearly 
demonstrate that acetylated WRN has markedly less helicase and exonuclease activities 
than unmodified WRN indicating that WRN acetylation reduces both helicase and 
exonuclease activities, at least on those simple substrates. Deacetylation of WRN could 
reverse this effect. However, it is believed that WRN physiological substrates are those 
formed during replication and recombination, including forks, since WRN has highest 
preference for those kinds of structures and possesses replication fork regression activity.  
Thus, a more depth analysis on various DNA structures, including replication forks, was 
done. For a 2-stranded fork and a 3-way junction substrate, the unwinding activity of 
unmodified WRN was substantially higher when compared with acetylated WRN. The 
difference in unwinding activities was less dramatic in the 3’ overhang substrate. 
However, the results of experiments performed using a replication fork showed 
approximately equivalent fork regression activities between both unmodified and 
acetylated WRN. Notably, the exonuclease activity on replication forks between 
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unmodified and acetylated WRN was also very similar. Collectively, our data strongly 
suggest that WRN acetylation helps to regulate WRN specificity for certain types of 
substrates.  
 
     Our studies here suggest that the effect of acetylation on WRN enzymatic function is 
DNA structure-dependent, with little or no effect on either regression or exonuclease 
activity on four-stranded replication forks. Since our previous studies demonstrated that 
WRN is acetylated in response to DNA damage and blockage of replication (see Chapter 
II), we speculate that WRN acetylation plays an important role in regulation of WRN 
function to resolve replication blockage. Specifically, acetylation may reduce WRN 
affinity for inappropriate DNA structures, while maintaining specificity for replication 
fork structures that are the putative physiological targets for WRN action. In support of a 
fundamental role of WRN during DNA replication, replication forks have been shown to 
be preferential targets for WRN function, since WRN acts more efficiently on forked 
DNA than double-stranded duplex DNA [Brosh et al., 2002; Compton et al., 2008] and 
regresses model replication forks in vitro [Machwe at al., 2006 and 2007], an important 
process to gain access to the replication-blocking lesion, allowing processive replication 
to resume once the blocking lesion is removed. The hypersensitity to replication blocking 
agents, prolonged S-phase and reduced lifespan observed in WRN-deficient cell lines are 
consistent with our notion as well. 
   
    Li and colleagues identified six lysine residues subject to acetylation on WRN [Li et 
al., 2010].  Moreover, they demonstrated that WRN acetylation was at the lowest level 
detected when all of the six lysines are mutated to arginines, by comparison with single, 
double, triple, and quadruple mutants, suggesting that all six lysines are involved in WRN 
acetylation. As part of this study, we analyzed if those six lysine residues are required for 
WRN enzymatic function. The results of our experiments revealed that these specific 
lysines are not required for WRN unwinding and exonuclease activities, indicating that 
these residues do not appear to be involved in catalysis and/or protein folding. The fact 
that arginine substitutions do not alter WRN’s catalytic activities on simple DNA partial 
duplexes structures contrasts with the effect on these activities when WRN is acetylated 
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on those lysine residues. Arginine residues cannot be acetylated but retain the positive 
charge, as for lysine residues. The positive charges of these amino acids are often 
involved in helping mediate binding to the negatively charged backbone of DNA. 
Acetylation of lysine eliminates this charge and therefore may alter DNA binding 
strength or specificity. Thus, our experiments suggest that acetylation of lysine residues 
on WRN might alter DNA binding affinity and enzymatic activities in such a way to 
lower the affinity for non-target DNA structures in favor of more physiological 
structures. It will be important to address in future experiments whether the relevance of 
individual lysine residues for DNA structure selectivity is altered by acetylation. 
Addressing these issues should also help to understand how WRN interacts with different 
DNA structures.  
 
     In summary, we have demonstrated that WRN acetylation helps to regulate WRN 
specificity for certain types of substrates, suggesting that WRN acetylation may increase 
specificity by reducing preference for non-physiological substrates. Importantly, our 
findings have identified that acetylation is likely involved in regulation of the DNA 
metabolic function of WRN. 
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CHAPTER IV 
 
WRN INTERACTION WITH RPA IN RESPONSE TO AGENTS THAT BLOCK 
REPLICATION 
 
INTRODUCTION 
      
     Existing evidence suggests an association of WRN with the process of DNA 
replication. Specifically, WS cells have dramatically reduced replicative capacity leading 
to very early cellular senescence; they grow slowly and have been reported to have a 
longer S phase and replication initiation and elongation abnormalities [Martin et al., 
1970; Takeuchi et al., 1982b; Salk et al., 1985; Poot et al., 1992; Yan et al., 1998]. In 
addition, WS cells are hypersensitive to DNA damaging agents that tend to block 
progression of replication forks such as interstrand crosslinking agents including 
mitomycin C and cisplatin, topoisomerase inhibitors such as camptothecin, and DNA 
replication inhibitors including HU [Gebhart et al., 1988; Ogburn et al., 1997; Poot et al., 
1999, 2001; Pichierri et al., 2001]. However, sensitivity of WS cells to DNA damaging 
agents does not appear to reflect a direct role in an established DNA repair pathway. 
Instead, sensitivity to both DNA damaging agents and HU suggests that WRN plays a 
role in responding to replication blockage by lesions or other obstructions.  
 
      A role for WRN in DNA replication likely involves key physical and functional 
interactions with other proteins involved directly or indirectly in completing duplication 
of the genome. In support of this notion, it has been reported that WRN associates or 
interacts directly with factors involved in DNA replication such as PCNA (which 
functions as a clamp to improve DNA polymerase processivity), FEN-1 (which processes 
the 5’ ends of Okazaki fragments in lagging strand DNA synthesis) [Lebel et al., 1999; 
Brosh et al., 2001b and 2002b; Rodriguez-Lopez et al., 2003; Sharma et al., 2005 ], and 
Topo I (which relaxes superhelical tension generated during DNA replication) [Lebel et 
al., 1999; Lane et al., 2003]. In addition, WRN interacts with DNA polymerase δ 
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[Kamath-Loeb et al., 2000 and 2001; Szekely et al., 2000], a major replicative DNA 
polymerase, and with RPA [Shen et al., 1998a and 2003, Brosh et al., 1999, Doherty et 
al., 2005, Sommers et al., 2005], a protein heterotrimer that protects single-stranded DNA 
and binds to gaps at blocked replication forks. Taken together, these observations suggest 
that loss of these interactions in WRN-deficient cells might disrupt key replication-
related pathways. Specifically, it has been suggested that WRN is involved either in 
preventing the collapse of stalled replication forks, or in the resolution of intermediates 
present at blocked forks. Consistent with this idea, recent studies have shown that:  1) 
WRN expression is upregulated during S and G2 phases in highly proliferative 
transformed cell lines [Kawabe et al., 2000b], 2) upon replication arrest, WRN is 
redistributed to distinct nuclear foci (associated with ongoing and/or blocked DNA 
synthesis) and is modified [Constantinou et al., 2000; Sakamoto et al., 2001], 3) WS cells 
have defective elongation showing marked asymmetry of replication forks from 
individual bidirectional origins [ Rodriguez-Lopez et al., 2002], and 4) WRN can 
coordinate its unwinding and pairing activities to regress a model replication fork 
substrate [Machwe et al., 2006]. Thus, the nature of genomic instability, increased cancer 
and premature aging observed in WS may be the result of improper resolution of blocked 
replication and illegitimate recombination caused by loss of WRN.  
   
      RPA is a single-stranded DNA binding protein complex composed of three structural 
subunits, RPA70, RPA32, and RPA14, that is involved in DNA replication, repair, and 
recombination [Iftode et al., 1999; Wold et al., 1997]. It has been shown that RPA binds 
to single-stranded gaps generated by stalled replication forks, helping to protect these 
regions and leading to the initiation of downstream pathways [Raderschall et al., 1999; 
Wold et al., 1997]. The initiation of those pathways requires the recruitment and 
activation of proteins such as ATR/ATRIP,  RAD17 complexes, and RAD51 [Dart et al., 
2004; Zou et al., 2003a and 2003b;  Binz et al., 2004; Jackson et al., 2002; Golub et al., 
1998], which are critical players for the DNA damage response. Importantly, DNA 
damage induces hyperphosphorylation (≥5 residues) of the N-terminal region of the 32 
kDa subunit of RPA [Binz et al., 2004; Din et al., 1990; Dutta et al., 1992; Mitsis et al., 
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1995,; Oakley et al., 2001; Shao et al., 1999], presumably to regulate its function in DNA 
metabolism.  
 
     Several studies have shown that purified recombinant RPA and WRN interact with 
each other and that RPA can stimulate WRN unwinding strength in vitro [Brosh et al., 
1999; Shen et al., 1998; Doherty et al., 2005], and it has been suggested that an 
interaction between WRN and RPA might occur in vivo within cells. Importantly, RPA 
colocalizes with WRN in nuclear foci after treatments that induce blockage of replication 
such as HU [Constantinou et al., 2000; Sakamoto et al., 2001; Ammazzalorso et al., 
2010]. Together, this evidence suggests that RPA and WRN might functionally interact at 
stalled replication forks. Thus, we were interested to examine the intracellular interaction 
between WRN and RPA, particularly in response to blockage of replication. Whether 
WRN-RPA association occurs via a direct stable interaction was also analyzed. The 
results of these experiments indicate that WRN and RPA form a direct association under 
normal physiological conditions in vivo and treatments that block replication fork 
progression result in an increased association between them. Thus, our findings further 
support the idea that WRN and RPA are involved in DNA replication by working in a 
complex at blocked or stalled replication forks.  
 
RESEARCH DESIGN      
 
SPECIFIC AIM: To study if genotoxins influence WRN interaction with RPA  
Aim a. To investigate if DNA damaging treatments (known as blockers of 
replication) regulate the intracellular interaction between WRN and RPA  
Aim b. To analyze whether WRN and RPA association occurs via a direct 
interaction 
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RATIONALE  
 
       The evidence of replication problems in WS cells and the sensitivity of these cells to 
inhibitors of replication suggest a direct physical and functional association of WRN with 
the process of DNA replication. To play such a role WRN must be located at forks or 
recruited to them when needed.  Consistent with this idea, WRN is subject to 
translocation from nucleolus to discrete sites, called nuclear foci, in response to DNA 
damage and replication blockers. These discrete subnuclear regions are considered as 
sites of DNA damage and blocked replication and therefore their formation is an 
important stage in DNA metabolism [Nelms et al., 1998].  Interestingly, WRN co-
localizes with RPA in these nuclear foci in response to treatment with the replication 
inhibitor HU [Constantinou et al., 2000]. Taken together, these facts support the notion of 
an association between WRN and RPA at blocked replication forks. Thus, based on 
previous evidence showing in vitro interaction between WRN and RPA, we hypothesized 
in this study that these factors interact directly within cells, particularly in response to 
replication blockers. Up to this point, an in vivo interaction between WRN and RPA had 
not been demonstrated. Therefore, we wanted to address if indeed an intracellular 
interaction between WRN and RPA exists in vivo, perhaps specifically in response to 
replication fork blockage.  If this hypothesis is true, blockage of replication by DNA 
damage should induce or increase WRN-RPA association. First, we used co-
immunoprecipitation experiments to investigate if WRN and RPA associate within cells 
(Aim a).  For these experiments, we treated cells with MMS and HU, agents known to 
induce blockage of replication, and studied their effect in the association between WRN 
and RPA. Then, we analyzed if WRN-RPA association occurs thru a direct protein-
protein interaction (Aim b).  
 
Aim a. To investigate if DNA damaging treatments (known as blockers of 
replication) regulate the intracellular interaction between WRN and RPA. The first 
specific question we wanted to address in regard to WRN and RPA interaction was: Do 
WRN and RPA interact within cells? First, co-immunoprecipitation experiments were 
used to examine possible association between WRN and RPA. The second question we 
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wanted to address was: Do DNA damaging treatments (that block replication fork 
progression) alter the nature of WRN interaction with RPA? For these experiments, we 
chose the DNA alkylating agent methylmethanesulfonate (MMS), which methylates the 
DNA bases, producing 7-methylguanine, 3-methyladenine and O6-methylguanine [Wyatt 
et al., 2006]. Importantly, WRN-deficient cells are hypersensitive to MMS and it induces 
specific lesions (7-methylguanine and 3-methyladenine) that physically block replication 
fork elongation in cells [Imamura et al., 2002; Harrigan et al., 2006, Groth et al., 2010].  
Additionally, we used the replication inhibitor HU, which depletes deoxyribonucleotide 
pools by inhibition of the enzyme ribonucleotide reductase, theoretically blocking 
progression of all replication forks [Skog et al., 1992, Pichierri et al., 2001]. As for MMS, 
WS cells are hypersensitive to HU, most likely by apoptosis of cells with stalled 
replication forks [Pichierri et al., 2001].  Thus, we used MMS and HU treatments to 
determine if DNA damaging treatments that block replication influence the interaction 
between WRN and RPA.  
 
Aim b. To analyze whether WRN and RPA association occurs via a direct 
interaction. Although a co-immunoprecipitation experiment from cells might indicate an 
association between two proteins, it does not prove a direct interaction between them. 
Within a protein complex, proteins might interact directly or indirectly via one or more 
bridging molecules, such as other proteins or nucleic acids (DNA or RNA). Thus, we 
wanted to analyze whether WRN and RPA association occurs via a direct interaction. 
Therefore, we tested whether purified WRN and RPA could directly bind to each other 
by Far Western analysis.  
 
METHODS  
  
WRN-RPA Co-immunoprecipitation Experiments. A co-immunoprecipitation assay is 
used to target a known protein that is believed to be a member of a larger complex of 
proteins (using an antibody specific for the known protein) to pull the entire protein 
complex out of solution and thereby identify other members of the complex. For our IP 
experiments, we used an SV40-transformed fibroblast cell line, 1-O, that was obtained 
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from J. Christopher States, University of Louisville [States et al., 1993]. 
Methylmethanesulfonate (MMS), phenylmethylsulfonylfluoride (PMSF), HU, and 
protease inhibitor cocktail were purchased from Sigma-Aldrich, and cell culture media 
and reagents were purchased from Invitrogen. Cells were grown in MEM-α Glutamax 
medium supplemented with 10% FBS, 1% HEPES, and 1% penicillin-streptomycin at 
37°C in a humidified atmosphere containing 5% CO2. For DNA damaging treatments, 
cells were incubated in medium containing 1 mM MMS for 4 h or 2 mM HU for 10 h 
before harvesting. For co-immunoprecipitation experiments, cells were lysed by 
sonication in RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% 
sodium deoxycholate, and 1 mM EDTA) supplemented with protease inhibitor cocktail, 1 
mM PMSF and 10 units/ml of DNase I (New England Biolabs). After centrifugation at 
21,000  g for 12 min at 4°C, supernatants were isolated and their protein concentrations 
measured. Samples (800 g of protein each) were pre-cleared with Protein G Plus/Protein 
A agarose beads (Calbiochem) and 1 g of normal mouse IgG (Santa Cruz) for 30 min, 
then incubated with mouse monoclonal anti-RPA32 antibody (Calbiochem) for 15 h at 
4°C. The samples were subsequently mixed with 30 μl of Protein G Plus/Protein A bead 
suspension at 4°C for 3 h. After collection by centrifugation and removal of supernatant, 
the beads were then washed three times with RIPA buffer supplemented with protease 
cocktail inhibitors, 1 mM PMSF and 200 g/ml ethidium bromide. After the final wash, 
equal portions of RIPA and 2X SDS sample buffer were added to the beads and 
immunoprecipitated proteins were released by heating at 95°C for 5 min. Equal volumes 
of each sample were resolved by SDS-PAGE (6% or 12% for WRN or RPA, 
respectively). Proteins were transferred to PVDF membranes (Bio-Rad) by 
electroblotting. The membranes were blocked with 5% nonfat dry milk in TBST buffer 
(20 mM Tris, pH 7.4, 140 mM NaCl and 0.1% Tween-20) and analyzed by Western 
analysis with rabbit anti-WRN (Santa Cruz) or mouse anti-RPA32 (Calbiochem) 
antibodies for 18 h at 4°C followed by chemiluminescent detection using ECL Plus (GE 
Healthcare). 
 
Far Western assays. Far Western blot analysis is a method used to study protein-protein 
interactions using an immobilized protein on a membrane to capture potential binding 
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partners that are then detected on the membrane using specific antibodies. Purified RPA 
(60 and 120 ng or 0.5 and 1 pmol, respectively) or recombinant WRN (30, 60 and 90 ng 
or 180, 360, and 540 fmol, respectively) and corresponding concentrations of bovine 
serum albumin (BSA) were spotted directly onto nitrocellulose membranes. After 
allowing the applied samples to dry for 15 min at 4°C, membranes were blocked for 1 h 
at 4°C with 5% nonfat dry milk in TBST. The membranes were then incubated in 5 ml of 
TBST-5% milk solution (including 25 mM NaCl or 100 mM NaCl as indicated) 
containing purified WRN (400 ng = 2.4 pmol) or RPA (360 ng = 3 pmol) for 3 h at 4°C. 
After washing three times for 10 min each with TBST, membranes were subjected to 
immunodetection by 1) incubation for 1 h with anti-WRN or anti-RPA32  antibody, 2) 
incubation for 1 h with appropriate HRP-linked secondary antibodies, 3) 
chemiluminescent development using ECL Plus (GE Healthcare) and 4) visualization by 
autoradiography. Films were scanned to assess the level of protein binding, with 
comparison to RPA standards spotted separately on the same membranes. 
 
RESULTS  
 
Blockers of replication enhance intracellular association of WRN with RPA. 
WRN has an important role in the maintenance of genomic integrity [Sidorova et al., 
2008], and accumulating evidence suggests its involvement in a DNA metabolic pathway 
that allows the cell to responds to replication blockage to maintain chromosomal stability. 
RPA participates in DNA replication and one of its roles is to bind and protect ssDNA 
formed during unwinding of the parental duplex and as a result of blockage of replicative 
DNA synthesis [Wold et al., 1997; Raderschall et al., 1999]. Interestingly, previous 
studies have shown WRN and RPA co-localization in nuclear foci in response to 
treatment with HU, indicating that these proteins function at the same site and suggesting 
that they might interact within a complex at blocked replication forks [Constantinou et 
al., 2000]. If so, it should be possible to detect interactions between WRN and RPA 
within cells in response to DNA damaging treatments known to block replication. To 
explore this possibility, we used co-immunoprecipitation methods that we developed 
earlier (see chapter II) to identify proteins that are putative members within a complex. If 
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WRN and RPA are part of the same complex, by targeting one of them with an antibody 
it is possible to pull the intact protein complex out of the cell (and thereby identify the 
other one as a member of the same complex). For these experiments, we use human 
fibroblasts treated either for 10 h with or without HU, an agent that blocks DNA 
replication by exhausting deoxynucleotide pools within cells, or for 4 h with or without 
the alkylating agent MMS, that produces methylated bases that block DNA replication. 
Both agents alter the subnuclear localization profile of WRN [Wyatt et al., 2006, 
Karmakar et al., 2005]. Since WRN and RPA possess DNA binding activities [Orren et 
al., 1999; Brosh et al., 2002; Bochkareva et al., 2002], it was possible that association 
might occur indirectly through DNA. Therefore, we used two strategies to minimize the 
possibility that protein interactions were mediated through DNA bridging: 1) DNase I 
was employed during lysis and immunoprecipitation to thoroughly digest DNA from 
protein samples, and 2) ethidium bromide was included during washing of the 
immunoprecipitate to intercalate DNA strands and thereby destabilize potential protein-
DNA interactions. A schematic representation of the protocol used is shown in Figure 
4.1. Briefly, we used an antibody against the RPA32 subunit for immunoprecipitation and 
antibodies against WRN and RPA32 for immunodetection. Analysis of 
immunoprecipitates by immunoblotting with RPA antibody demonstrated that the level of 
RPA was equal in the immunoprecipitated fraction in HU- and MMS-treated and 
untreated cells (Figure 4.2A, lower panel), indicating that we immunoprecipitated 
equivalent amounts of RPA in each sample and that RPA expression or abundance not 
changed by HU or MMS treatment. Even in untreated cells, we were able to detect 
endogenous WRN co-immunoprecipitated along with RPA, demonstrating an association 
between WRN and RPA even in the absence of exogenous damage (Figure 4.2, upper 
panel, lanes 2 and 5). Interestingly, the amount of WRN precipitated with RPA is 
substantially higher in MMS-treated cells (Figure 4.2A, upper panel, lanes 2 vs. 3). 
Similar results were obtained with HU-treated cells (Figure 4.2A, lanes 5 vs. 6). 
Quantitation of data from multiple independent experiments indicates that MMS results 
in a 4.4 fold increase and HU results in a 2.0 fold increase in the levels of WRN 
interacting with RPA (Figure 4.2B). Thus, WRN and RPA are co-immunoprecipitated  
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               Figure 4.1 Schematic representation of the procedure used 
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Figure 4.2 DNA damage enhances the co-immunoprecipitation of WRN with RPA. 
A) Cells incubated with or without MMS (1 mM) for 4 h or HU (2 mM) for 10 h were 
prepared for immunoprecipitation using anti-RPA32 subunit monoclonal antibody as 
described in Methods. Aliquots (40 μl) of the resuspended immunoprecipitated fractions 
from untreated (lanes 2 and 5), MMS-treated (lane 3), and HU-treated (lane 6) lysates 
were analyzed by SDS-PAGE (6%) and Western blotting using anti-WRN antibody and 
chemiluminescent detection (upper panel). In parallel, aliquots (2.5 μl) of these same 
immunoprecipitated fractions were analyzed by SDS-PAGE (12%) and Western blotting 
using anti-RPA32 antibody (lower panel). Purified WRN and RPA were loaded as 
protein markers (Mkr, lanes 1 and 4). B) Quantitative bar graph for WRN-RPA 
interaction under conditions described above (mean and S.D. for three independent 
experiments). 
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from cell lysates, suggesting that they are associated within the same complex in vivo. 
More importantly, this interaction is significantly increased following treatments known 
to block DNA replication. 
 
WRN and RPA association occurs via a direct interaction. The experiments above 
show an association between WRN and RPA in vivo.  However, proteins might interact 
directly or indirectly, via one or more linked proteins. Thus, we wanted to analyze 
whether WRN and RPA association occurs via a direct interaction. Thus, we tested 
whether purified WRN and RPA could bind to each other by a Far Western dot blotting 
method that is used to analyze specific protein-protein interactions. Briefly, several 
concentrations of one protein were immobilized on nitrocellulose membranes. The 
membranes were blocked with 5% milk solution to saturate any non-specific binding sites 
and then incubated in buffer containing the other protein of interest. As a control for non-
specific binding, the same amounts of BSA were separately spotted onto the same 
membrane. Then, membranes were subjected to immunodetection by incubation with 
anti-WRN or anti-RPA32 antibodies to assess binding of the proteins. Figure 4.3A shows 
that when RPA was spotted onto the membrane, WRN binds to RPA in a manner 
dependent on the RPA concentration. Similar results were obtained when WRN was 
spotted onto the membrane. Specifically, RPA bound exclusively to WRN in amounts 
dependent on WRN concentration (Figure 4.3B). No non-specific binding of WRN or 
RPA to BSA was observed. Additionally, we tested the stability of WRN-RPA 
interaction. To this end, we analyzed the effect of increasing concentrations of NaCl on 
the WRN-RPA interaction. Interestingly, similar amounts of RPA bound to WRN at 
NaCl concentrations of 25 mM and (more physiologically relevant) 100 mM (Figure 
4.3B). Therefore, we can conclude that WRN and RPA association occurs via a direct, 
salt tolerant interaction.   
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Figure 4.3 RPA and WRN directly interact with each other. For Far Western analysis, 
purified RPA (A), WRN-E84A (B), and BSA (both, as a control for non-specific binding) 
were immobilized on nitrocellulose membranes at the concentrations indicated above 
each panel. After blocking, membranes were then incubated in buffer containing 25 or 
100 mM NaCl as indicated at left and either (A) WRN-E84A (400 ng = 2.4 pmol) or (B) 
RPA (360 ng = 3 pmol). As described in Methods, immunodetection and autoradiography 
were used to assess binding of the protein in solution to the immobilized protein on the 
membrane. The amounts of RPA bound to immobilize WRN (indicated below 
corresponding spots in B) were determined by comparison to an RPA standard (50 fmol) 
spotted on each membrane. 
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DISCUSSION 
 
     To safeguard genome stability, cells rely on an accurate response to replication stress. 
The observed enhanced genomic instability and diminished replicative lifespan of WS 
cells highlight the importance of WRN in DNA metabolism and maintenance of genomic 
stability. Several lines of evidence support the view that WRN might play a critical role 
in the response to replication stress, specifically in the response to stalled replication 
forks. In agreement with this notion, WRN co-localizes with replication factors, including 
RPA, in response to treatment with DNA damaging agents and the replication inhibitor 
HU [Constantinou et al., 2000]. Therefore, it should be possible to detect interactions 
between WRN and RPA in vivo, particularly in response to replication blocking agents.  
 
     In this study we clearly demonstrate, by co-immunoprecipitation experiments, an 
association between WRN and RPA in vivo. Importantly, we also demonstrated that 
WRN-RPA interaction significantly increased after MMS and HU, agents known to block 
replication. This is the first time that co-immunoprecipitation of endogenous WRN and 
RPA has been demonstrated, as well as its enhancement by genotoxins. These results 
indicate that, in response to replication blockage, WRN and RPA associate in the same 
protein complex in vivo. This binding appeared not to be mediated by DNA, because the 
interaction persists in the presence of ethidium bromide and DNase I and is substantially 
increased after MMS or HU treatment. Our results are consistent with studies 
demonstrating that WRN and RPA orthologs in C.elegans cooperate at blocked 
replication forks after HU, and that WRN is required for the efficient formation of RPA 
foci in response to DNA replication inhibition [Yan et al., 1998, Lee et al., 2010].  
 
     Although our results support the notion that WRN and RPA play a part in the same 
protein complex, they do not prove a direct physical association between them. Hence, 
we tested whether recombinant WRN and purified RPA could bind to each other by Far 
Western dot blotting analysis. The results demonstrated that WRN bound RPA directly. 
Notably, the interaction is stable even at physiologically relevant salt concentrations. 
Taken together, our data strongly suggest that co-immunoprecipitation of WRN and RPA 
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is mediated by a direct interaction between them. Importantly, our results are consistent 
with previous reports showing a direct interaction between purified WRN and RPA.  
According to these studies, the interaction between WRN and RPA occurs thru the N-
terminal region of WRN (aa239-499) and the RPA70 subunit (aa100-300) [Brosh et al., 
1999; Doherty et al., 2005; Shen et al., 2003].   
 
     It is believed that during DNA replication different DNA lesions can pose a serious 
threat to genome integrity by interfering with fork stability. Those lesions will influence 
how the blocked replication fork structure will be processed to restart DNA replication. 
Proposed models for resolution of replication blockage suggest that one of the first steps 
involves fork regression to generate a Holliday junction or “chicken foot” intermediate 
[Haber et al., 1999; Cox et al., 2002]. The unwinding and annealing activities of WRN 
suggest that WRN would be suitable to perform fork regression. In response to HU 
treatments, WRN is subject to translocation from nucleolus to nuclear foci (considered as 
sites of blocked replication) where it co-localizes with RPA [Constantinou et al., 2000]. 
This evidence suggests that WRN and RPA might interact at blocked replication forks, 
facilitating WRN function in proper resolution of replication blockage. Consistent with 
this notion, several studies have shown that: 1) RPA enhances WRN unwinding strength 
[Shen et al., 1998a; Brosh et al., 1999], 2) WRN has a preferential action on complex 
DNA structures, including replication forks [Huang et al., 2000; Brosh et al., 2001; 
Opresko et al., 2004; Orren et al., 2002], 3) WRN specifically regresses replication forks 
[Machwe et al., 2006], and 4) WRN displaces RPA from a replication fork substrate 
independently of its catalytic activity and subsequently remodels/regresses this 
replication fork [Machwe et al., 2011]. Based on these findings, we propose a possible 
scenario as to how WRN and RPA might function cooperatively to resolution of stalled 
replication forks. Upon replication blockage, RPA binds to resulting single-stranded 
DNA gaps and helps to recruit WRN to blocked forks via a direct interaction between 
these two proteins. WRN regresses the fork and displaces RPA in the process. 
Subsequently, the regressed fork is subsequently processed and replication is restarted. 
Since we previously demonstrated that WRN is modified, specifically acetylated, in 
response to DNA damage and/or replication blockage, and WRN acetylation [Blander et 
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al., 2002] and phosphorylation [Pichierri et al., 2003] correlates with its relocalization 
from nucleolus to nuclear foci where it colocalizes with RPA, it is possible that a 
modified form of WRN might mediate or enhance the WRN-RPA interaction.    
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
     The primary objective of our studies was to further clarify the role of WRN in 
response to agents that damage DNA and/or block replication, with a particular emphasis 
on the relationship of acetylation of WRN with its function in DNA metabolism. In 2002, 
Blander et al. made the observation that WRN can be acetylated in vivo by the 
acetyltransferase p300 [Blander et al., 2002], and that this modification correlates with its 
translocation from the nucleolus into nucleoplasmic foci. These findings suggested that 
WRN acetylation could play an important role in regulation of WRN function, a concept 
that has been reinforced by the experiments presented here. It is also noteworthy that 
WRN is also subject to phosphorylation and sumoylation. 
  
     In Chapter II, we addressed the dynamics of endogenous WRN acetylation and its 
relationship to DNA damage. To this end, we measured the levels of WRN acetylation 
after DNA damaging agents and replication blocking agents. The results of those 
experiments revealed that WRN is detectably acetylated under normal conditions. 
However, certain DNA damaging agents (MMS, MMC, cisplatin, but not UV) and 
inhibitors of DNA replication such as HU significantly increase WRN acetylation. Our 
results are consistent with a study showing WRN acetylation after treatments with DNA 
damaging agents, such as MMC [Karmakar et al., 2005]. Importantly, our results using 
inhibitors of standard repair pathways to suppress DNA damage removal extend those 
observations in two ways. First, our results confirm that WRN acetylation itself is, at 
least in part, related directly to DNA damage and not some non-specific effect of the 
treatment on some other aspect of cellular metabolism or physiology. Second, since we 
demonstrated that inhibition of repair of certain lesions induced further amplification of 
WRN acetylation, our results revealed that it is not the induction of damage but its 
persistence that optimally enhances WRN acetylation. Thus, our results suggest that 
WRN acetylation is a downstream effect of certain types of DNA lesions on DNA 
metabolism. Since all of the agents that enhance WRN acetylation in our studies are 
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known to either directly cause or produce lesions that result in blockage of replication, 
the results of our experiments strongly suggest that WRN might be acetylated in response 
to stalled or blocked replication. In agreement with this notion, we showed that increases 
in the levels of acetylated WRN correlate with inhibition of DNA synthesis and an 
increase in the percentage of S-phase cells.   
 
    Since the acetylation state of proteins in humans is regulated by acetylases and 
deacetylases, we used deacetylase inhibitors to investigate the role of deacetylases in 
regulation of WRN acetylation. The results of our experiments revealed that WRN is 
actively deacetylated in vivo and that, even in untreated cells, WRN acetylation state is 
determined by an equilibrium between acetylation and deacetylation. These results are in 
agreement with studies showing WRN regulation in response to deacetylase inhibitors, 
since it has been shown that WRN translocates from the nucleolus to nucleoplasmic foci 
in response to TSA treatment [Blander et al., 2002]. Since our previous studies 
demonstrated enhancement of WRN acetylation after DNA damaging and replication 
blocking treatments, a possible explanation for our results is that blockage of replication 
by DNA damage or other circumstances shifts the equilibrium towards acetylation. 
Previous studies have shown that WRN function is influenced by the sirtuin family of 
deacetylase enzymes, including SIRT1 [Li et al., 2008 and 2010; Law et al., 2009; Kahyo 
et al., 2008; Michishita et al., 2008]. Notably, we demonstrated for the first time that 
members of the classical HDAC family of deacetylase enzymes appear to play a role in 
WRN deacetylation. In fact, our results suggest that HDACs may play the predominant 
role, since inhibition of HDACs (using TSA) resulted in higher levels of WRN 
acetylation when compared to inhibition of sirtuins (using nicotinamide).  
 
        To investigate the effect of WRN acetylation on its biochemical function, 
unmodified, acetylated, and deacetylated WRN were compared as to their helicase, 
exonuclease and fork regression activities on different DNA structures. Our data 
demonstrated that acetylated WRN has dramatically less helicase and exonuclease 
activities than unmodified WRN on simple DNA substrates. Conversely, deacetylation of 
WRN restored the helicase and exonuclease activities to near normal levels. These 
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experiments initially suggested that WRN acetylation might regulate WRN enzymatic 
function in a negative manner. However, since WRN has preference for complex DNA 
structures, such as DNA replication and recombination intermediates, we explored WRN 
action on those kinds of substrates. When a more rigorous examination was performed on 
complex DNA substrates (such as replication forks), the effect of acetylation on WRN 
fork regression activity and exonuclease activity on those substrates was substantially 
less pronounced. Collectively, our results suggest that WRN acetylation regulates WRN 
specificity by reducing its preference for non-physiological DNA substrates. This 
supports the idea that WRN acetylation is likely to be critical for its contribution to 
genomic integrity surveillance. Since our data indicate that WRN acetylation might 
increase WRN specificity by reducing preference for non-physiological substrates, 
further DNA binding assays are required to explore if the binding of acetylated WRN to 
the different DNA structures correlates with the results obtained in our helicase, 
exonuclease, and fork regression assays. Based on our results, we speculate that WRN 
acetylation (as well as other post-translational modifications) may serve as a rapid way to 
respond to cellular stress and restart replication. By this reasoning, acetylation may be 
involved in reducing WRN affinity for nucleolar DNA while maintaining affinity for 
replicative DNA structures associated with replication foci. Consistent with this notion, 
previous studies have shown that WRN acetylation correlates with its translocation to 
nuclear foci in response to DNA damage and replication blockers [Blander et al., 2002; 
Karmakar et al., 2005].  WRN also assists the pairing of complementary DNA strands. 
Thus, unmodified and acetylated WRN should be compared in future experiments to 
investigate the effect of acetylation on WRN annealing activity.       
  
     In our experiments, we measured overall acetylation of WRN. Interestingly, our 
results suggest that the status of WRN acetylation might be regulated by different 
conditions, such as DNA damage and disruption of the equilibrium between acetylases 
and deacetylases. However, it is unclear if independent acetylation events occur on 
different lysine sites upon different conditions and/or DNA damaging treatments.  A 
recent study identified putative acetylated lysine residues (K366, K887, K1117, K1127, 
K1389, and K1413) in WRN using ectopically expressed WRN and the acetylases p300 
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and CBP [Li et al., 2010]. However, it would be informative and more physiologically 
relevant to identify WRN acetylation sites on endogenous WRN, using mass 
spectrometry analysis. Such an analysis would explore if, indeed, all or a subset of these 
residues are the actual sites subject to acetylation in the native environment of cells--i.e, 
with endogenous levels of WRN and the relevant acetylases. The same technique can be 
used after treatment of cells with the different DNA damaging agents, or the deacetylase 
inhibitors, to explore differential patterns of acetylation between the different treatments. 
The immunoprecipitation protocols developed for these studies should be useful for 
isolating modified and unmodified WRN for these types of experiments. If the different 
treatments target different residues, those studies should provide valuable insight in 
regard to functional differences between the various acetylation events and if there is any 
hierarchy in the acetylation of different lysine residues.  In addition, site-directed 
mutagenesis can be used to mutate the putatively acetylated lysines to investigate which 
modifications affect WRN biochemical activities. Specifically, those mutants can be used 
in DNA binding assays as well as helicase and exonuclease assays, to determine if 
specific mutations (or combinations of mutations) affect the interaction of lysine residues 
with the negatively charged backbone of DNA. To directly determine the effect of WRN 
acetylation on its cellular function, WRN cDNAs containing lysine to arginine (a 
conservative basic substitution that cannot be acetylated) point mutations at putative 
acetylation sites can be constructed and transfected into WRN-deficient cells to compare 
the ability of wild-type and acetylation-deficient WRN to complement the 
hypersensitivity of WS cells to HU and DNA damaging agents as well as other 
phenotypes of WRN-deficient cells.    
 
     The data described herein suggest that WRN is regulated in response to DNA damage 
and replication blocking agents. To confirm this relationship and investigate it further, we 
analyzed if DNA damage regulates the nature of WRN’s potential interactions in 
response to treatments that block replication. Specifically, we investigated the potential 
interaction between WRN and the single-stranded DNA binding protein complex, RPA, 
and whether it is altered in response to treatment with HU or MMS.  Our experiments 
revealed that WRN and RPA associate with each other even under normal physiological 
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conditions in vivo. Interestingly, treatments that block replication fork progression induce 
an increased association between these two factors. As we also demonstrated that purified 
WRN and RPA bind to one another, this association in vivo is also likely to be direct. The 
results of our experiments confirm previous findings showing interaction between 
purified WRN and RPA [Brosh et al., 1999; Doherty et al., 2005; Shen et al., 2003]. 
Importantly, our results substantially extended those findings by showing endogenous 
WRN-RPA interaction in the native environment of cells, as well as its enhancement by 
treatments that block replication. It is known that RPA is hyperphosphorylated in 
response to treatment with DNA damaging agents and replication blocking agents 
[Oakley et al., 2001; Shao et al., 1999; Anantha et al., 2009]. Thus, future co-
immunoprecipitation experiments could be performed to analyze if WRN specifically or 
preferentially interacts with the hyperphosphorylated form of RPA. On the other hand, 
the addition of acetyl groups to lysine residues on WRN after DNA damage may create a 
new surface for protein association(s). Thus, it will be interesting to explore as well 
whether and how acetylated forms of WRN interact with RPA and if this is influenced by 
treatment with agents that block replication. 
           
     In summary, through this study, we provided some interesting and revealing results 
that support the likely importance of WRN regulation in response to DNA damage and 
blockage of replication. Collectively, our results suggest that WRN acetylation is a 
downstream effect of DNA damage on DNA metabolism which influences WRN 
function, including altering its specificity by reducing preference for non-physiological 
substrates. Thus, the results of the studies presented in this work have identified unique 
mechanisms by which WRN is regulated in response to DNA damage. Importantly, our 
results are consistent with evidence pointing to a role for WRN in response to blocked 
replication, including its recruitment to sites of ongoing and/or blocked replication upon 
DNA damage and its ability to regress model replication forks. Based on our findings and 
the existing evidence, we propose a possible scenario for how loss of WRN function 
(possibly caused by problems with regulation of WRN acetylation) in DNA metabolism 
might result in the cancer and premature aging phenotypes typically associated with WS 
(Figure 5.1).  An inability to properly resolve blocked replication forks, due to loss or 
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Figure 5.1 Schematic representation of the downstream effects caused by loss of 
WRN function. Loss of WRN function (possibly caused by problems with regulation of 
WRN acetylation) in DNA metabolism might result in the inability of cells to properly 
resolve replication blockage and thereby increase genomic instability. These DNA 
metabolic problems might cause chromosomal abnormalities and activate checkpoints 
that, in turn, might trigger cell death and cellular senescence; processes that result in the 
accelerated development of age-related phenotypes and elevated cancer frequency 
associated with WS. 
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dysfunction of WRN, may further delay or cause collapse of DNA replication, triggering 
overall genomic instability and activation of checkpoint pathways that, in turn, might 
trigger cellular senescence and cell death; two mechanisms that are thought to drive 
certain aging processes. Genomic instability may also contribute to chromosomal 
aberrations, potentially driving carcinogenesis. This model would be consistent with the 
increased cancer incidence and aging phenotypes in WS. However, further research is 
needed to determine if, indeed, acetylation of WRN is essential to minimize large-scale 
chromosomal aberrations and prevent the development of age-related phenotypes.  To 
investigate the role of acetylated WRN in the pathogenesis of aging, WRN cDNAs 
containing lysine mutations at putative acetylation sites can be constructed and 
transfected into WRN-deficient cells to compare the ability of wild-type and acetylation-
deficient WRN to complement the premature cellular senescence of WS cells as well as 
other age-related phenotypes of WRN-deficient cells. The same strategy can be used to 
measure genomic instability, using techniques such as the micronucleus assay, to 
determine whether and to what extent loss of WRN acetylation might contribute to the 
development of cancer. Alternatively, loss of function or dysregulation of acetylases and 
deacetylases that disrupt the equilibrium in the process of WRN acetylation might also be 
used as a possible strategy. Thus, creating a cell culture model in which the balance 
between acetylation and deacetylation is altered by knocking down and/or overexpressing 
specific deacetylases and acetylases involved in the WRN acetylation process, such as 
p300, may help to determine the importance of acetylated WRN in processes such as 
cellular senescence and carcinogenesis. To examine whether WRN acetylation was 
required for suppression of age-related and cancer phenotypes at the physiological level, 
specialized transgenic mouse models would have to be developed in which mutated 
WRN genes, incapable of acetylation as described above but otherwise catalytically 
unaffected, are re-introduced into mice lacking functional WRN and telomerase; notably, 
telomerase deficiency is necessary to reveal WRN-related cancer and aging phenotypes 
in mice (Chang et al. 2004). Although many questions regarding WRN acetylation and its 
function remain to be answered, our findings provided mechanistic insights into the role 
of WRN in DNA metabolism. Importantly, our work revealed that WRN acetylation is a 
fascinating area of research to keep our attention well into the future.  
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 APPENDIX 
 
LIST OF ABBREVIATIONS 
 
ATM: Ataxia telangiectasia mutated protein kinase 
ATP: Adenosine triphosphate 
ATR: ATM and Rad3-related protein kinase 
BER: Base Excision Repair  
BLM: Bloom Syndrome Protein 
BN: Binucleated 
bp: Base pairs 
BrdU: Bromodeoxyuridine 
CBP: CREB-binding protein 
cDNA: complementary DNA 
DNA: Deoxyribonucleic acid 
DNA-PK: DNA-dependent protein kinase 
EDTA: Ethylenediaminetetraacetic acid 
FEN-1: Flap Endonuclease I 
fmol: femtomol  
HAT: Histone acetyltransferase 
HDACs: Histone Deacetylases 
HEK293: Human Embryonic Kidney 293 cells 
HRDC: Helicase and RNase D C-terminal  
HU: Hydroxyurea 
IP: Immunoprecipitation 
MGMT: Methylguanine methyltransferase 
MMC: Mitomycin C 
MMS: Methylmethanesulfonate 
MN: Micronucleus 
MRK: Marker 
NAD+: Nicotinamide adenine dinucleotide 
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N.D.: Non-detectable 
NER: Nucleotide Excision Repair 
NER+: Nucleotide Excision Repair Proficient 
NER-: Nucleotide Excision Repair Deficient 
NIC: Nicotinamide  
O6-BG: O6-benzylguanine 
PARP: Poly (ADP-ribose) polymerase 
PCNA: Proliferating Cell Nuclear Antigen 
pmol: picomol  
PMSF: Phenylmethylsulfonylfluoride 
PVDF: Polyvinylidene Fluoride 
RPA: Replication Protein A 
RECQ: RecQ helicase 
RQC: RecQ-conserved 
S.D.: Standard Deviation   
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SIRT1: Sirtuin 1  
ssDNA: Single-stranded DNA 
SUMO: Small Ubiquitin-like Modifier 
TOPO I: Topoisomerase I 
TSA: Trichostatin A 
UV: Ultraviolet 
WB: Western Blot 
WRN: Werner Protein 
WS: Werner Syndrome 
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ACADEMIC TRAINING/PROFESSIONAL EDUCATION 
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